Document:

<PAGE>
                                                                    Exhibit 10.1
                       MANUFACTURING AND SUPPLY AGREEMENT

      THIS MANUFACTURING AND SUPPLY AGREEMENT (the "AGREEMENT") is made and
entered into as of November 16, 2006 (the "EFFECTIVE DATE") by and between ALTUS
PHARMACEUTICALS INC., a Delaware corporation with offices at 125 Sidney Street,
Cambridge, MA 02139-4807 ("ALTUS"), and LONZA LTD, a Swiss corporation having
offices at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (the "LONZA").
Each of Altus and Lonza may be referred to herein individually as a "Party" and
collectively as the "Parties".

                                    RECITALS

      WHEREAS, Altus and Lonza are parties to a Letter of Intent dated as of
[***], which has been amended by the Parties as of [***] by [***] and as of
[***] by [***] (collectively, the "Letter of Intent"), and to a Technology
Transfer Agreement dated as of [***];

      WHEREAS, Altus is engaged in the development and commercialization of
pharmaceutical products, including an orally delivered product for enzyme
replacement therapy for the treatment of malabsorption as a result of pancreatic
insufficiency;

      WHEREAS, Lonza possesses certain processes, technology and facilities for
manufacturing microbial fermentation materials, including proteins, for use in
pharmaceutical products; and

      WHEREAS, pursuant to the Letter of Intent, the Parties have agreed upon
the basic terms under which Lonza shall manufacture and supply to Altus certain
proteins in bulk form for use by Altus in preparing its enzyme replacement
product, as set forth in this Agreement;

      NOW, THEREFORE, in consideration of the forgoing and the covenants and
promises in this Agreement, Altus and Lonza hereby agree as follows:

                                   ARTICLE 1

                                   DEFINITIONS

      As used in this Agreement, the following capitalized terms shall have the
following meanings:

      1.1 "ACCEPTANCE TESTS" means the specific tests to be used to determine
whether Bulk Product Component supplied to Altus conforms to the applicable Bulk
Specifications, which tests are established (and amended from time to time if
required) in writing by Altus in consultation with Lonza.

      1.2 "AFFILIATE" means, with respect to a Party, any other business entity
that directly or indirectly controls, is controlled by, or is under common
control with, such

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       1.
<PAGE>

person or entity. For purposes of this definition only, "control" (with
correlative meanings for the terms "controlled by" and "under common control
with") shall mean that the applicable Party has the actual power to direct or
cause the direction of the management and policies of the subject entity,
whether through the ownership of voting stock or partnership interest, by
contract or otherwise. In the case of a corporation, the direct or indirect
ownership of fifty percent (50%) or more of its outstanding voting shares or the
ability otherwise to elect a majority of the board of directors or other
managing authority of the entity shall in any event be deemed to confer control,
it being understood that the direct or indirect ownership of a lesser percentage
of such shares shall not necessarily preclude the existence of control.

      1.3 "ALTUS MANUFACTURING TECHNOLOGY" means all Information that is
Controlled by Altus and relates directly to the manufacture of any Bulk Product
Component, and any intellectual property rights (including any patents) that are
Controlled by Altus and claim, cover or are appurtenant to any such Information.

      1.4 "ALTUS IP" means (a) all patents or patent rights that are Controlled
by Altus and claim a Product Component or its manufacture, or any Altus
Manufacturing Technology, and (b) any other intellectual property rights that
are Controlled by Altus and cover or are appurtenant to any Altus Manufacturing
Information.

      1.5 "ANNUAL ORDER" shall mean the Purchase Order submitted by Altus by
October 15 of a particular year, covering its initial orders of Batches of each
Bulk Product Component to be manufactured and delivered by Lonza in the
following calendar year, as provided in Section 3.2.

      1.6 "APPLICABLE LAW" means any applicable laws, rules and regulations,
including any rules, regulations, guidelines or other requirements of relevant
government agencies, that may be in effect from time to time in the applicable
country or jurisdiction.

      1.7 "BATCH" means, as to particular Bulk Product Component, the total
amount of such Bulk Product Component, as applicable, resulting from one
complete production run conducted by Lonza using the Manufacturing SOPs
applicable to such Product Component, and including the Batch Records applicable
to such production run.

      1.8 "BATCH RECORDS" means, with respect to a particular production run
conducted by Lonza for manufacturing one batch of a particular Product
Component, the completed batch records, in the form of the Master Batch Records,
containing all the relevant manufacturing details and information for such
production run, including any deviations.

      1.9 "BULK PRODUCT COMPONENT" means one of the three Product Components, in
bulk form as described in EXHIBIT A of this Agreement.

      1.10 "BULK SPECIFICATIONS" means, with respect to particular Bulk Product
Component, the specifications, characteristics, labeling, and packaging
requirements and standards for such Bulk Product Component as set forth in
EXHIBIT B of this Agreement,

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       2.
<PAGE>

as the same may be amended or supplemented from time to time by Altus.

      1.11 "CERTIFICATE OF ANALYSIS" means a written certificate of analysis, in
the form set forth in EXHIBIT C of this Agreement, which confirms that the
quantity of the applicable Bulk Product Component in a particular Batch
manufactured and delivered by Lonza has been tested in accordance with the
applicable Acceptance Tests and meets the applicable Bulk Specifications. The
Certificate of Analysis will include the results of all Acceptance Tests
performed by or on behalf of Lonza on the particular Batch of Bulk Product
Component.

      1.12 "CHF" means Swiss francs.

      1.13 "CLAIMS" has the meaning set forth in Section 7.1.

      1.14 "CMC SECTION" shall mean the "chemistry manufacturing and control"
section of any Regulatory Application, as defined the relevant Applicable Laws.

      1.15 "CONFIDENTIAL INFORMATION" shall have the meaning ascribed to such
term in Section 10.1.

      1.16 "CONFIDENTIALITY AGREEMENT" means the Confidentiality Agreement
between Altus and Lonza dated [***].

      1.17 "CONTROLLED" means, with respect to a specific material, item of
Information or intellectual property right, that a Party owns or has a license
to such material, item or right and has the ability to grant the other Party
access and a license thereto as provided in this Agreement without violating or
conflicting with any agreement with or rights of a Third Party.

      1.18 "CURRENT GOOD MANUFACTURING PRACTICE" or "CGMP" means the
then-current standards for the manufacture of pharmaceutical products, pursuant
to (a) the FD&C Act (21 U.S.C. 321 et seq.); (b) relevant United States
regulations in Title 21 of the United States Code of Federal Regulations
(including Parts 11, 210, and 211); (c) EC Directive 2003/94 EC of October 8,
2003; (d) the EC Guide to Good Manufacturing Practice for Medicinal Intermediate
Products; (e) International Conference on Harmonization (ICH) ICH Q7A Good
Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; and (f)
all additional Regulatory Authority documents or regulations that replace,
amend, modify, supplant or complement any of the foregoing.

      1.19 "DEFECTIVE PRODUCT" has the meaning set forth in Section 4.4.

      1.20 "DISCLOSING PARTY" has the meaning set forth in Section 8.1.

      1.21 "EXCESS ORDERS" shall have the meaning ascribed to such term in
Section 3.3.

      1.22 "FDA" means the United States Food and Drug Administration, or any
successor thereto having the administrative authority to regulate the
development and

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       3.
<PAGE>

marketing of human pharmaceutical products in the United States.

      1.23 "FD&C ACT" means the United States Food, Drug and Cosmetic Act, as
amended, and any regulations promulgated thereunder.

      1.24 "FINAL PRODUCT" means any pharmaceutical product containing the
appropriate quantities of each Product Component supplied by Lonza hereunder as
Bulk Product Components.

      1.25 "INFORMATION" means any and all information, results and data,
including discoveries, improvements, processes, methods, protocols, formulas,
techniques, inventions, know-how and trade secrets, scientific, chemical,
pharmaceutical, toxicological, biochemical, and biological, data, and
information relating to the results of tests, assays, methods, processes, and
specifications, and/or other documents containing information and related data,
and any assay control, regulatory, and any other test results or information,
regulatory, manufacturing, financial and commercial information or data.

      1.26 "LONZA DEVELOPMENT SITE" means the Lonza facility located at [***],
which shall be used to conduct some of the technology transfer and development
work contemplated under this Agreement.

      1.27 "LONZA FACILITY" means the applicable manufacturing suite ([***]) at
Lonza's manufacturing facility located at [***], or any other manufacturing
facility that is owned or controlled by Lonza or its Affiliate and is agreed to
by Altus in writing to be used to manufacture Bulk Product Components.

      1.28 "LONZA TECHNOLOGY" means any Information, and all intellectual
property rights (including patents) claiming, covering or otherwise appurtenant
to such Information, that is Controlled by Lonza and may be useful in
manufacturing Bulk Product Component, including QA/QC testing and processes.

      1.29 "MANUFACTURING INVENTION" means any Information (and all intellectual
property rights claiming, covering or otherwise appurtenant to such Information)
that (a) relates to manufacture of Bulk Product Component, or to Product
Component or its use, including any such Information relating manufacturing
methods, processes, uses or compositions, and (b) that is made, created,
developed, conceived and/or reduced to practice by a Party or its Affiliates, or
by the Parties (and/or their Affiliates) jointly, in the course of conducting
activities under this Agreement or the Tech Transfer Agreement.

      1.30 "MANUFACTURING SCHEDULE" has the meaning ascribed in Section 3.2(a).

      1.31 "MANUFACTURING SOPS" means, as to a particular Bulk Product
Component, the specific methods, techniques, processes and standard operating
procedures that are to be used by Lonza to manufacture such Bulk Product
Component, including the applicable Quality Control Procedures applicable to
such Bulk Product Component.

      1.32 "MASTER BATCH RECORDS" means, as to a particular Bulk Product

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       4.
<PAGE>

Component, the master batch records for such Bulk Product Component as
established by the Parties under Section 2.2, including the applicable
Manufacturing SOPs, the in-process testing and QA/QC testing for such Bulk
Product Component, which are to be used in the manufacture by Lonza hereunder of
such Bulk Product Component.

      1.33 "MATERIALS" means the specific cell lines, cell banks, reagents,
reference standards and/or other materials as Altus may deem necessary to be
transferred to Lonza in order for Lonza to manufacture Bulk Product Components.

      1.34 "MAXIMUM CAPACITY" means, as to the applicable Lonza Facility, the
total number of Batches of a particular Bulk Product Component (or Bulk Product
Components, as applicable) that can be produced in one calendar year at such
Lonza Facility, with such Lonza Facility operating [***] per day and for [***]
in the year (and including, if such Maximum Capacity is to be determined for
[***] Bulk Product Components manufactured at such Lonza Facility in the year,
the actual minimum [***] for the change over of the Lonza Facility from the
first Bulk Product Component to the [***]). Starting in [***], the Maximum
Capacity for a particular Lonza Facility will be determined, by extrapolating to
a full calendar year the actual manufacturing cycle times experienced by Lonza
in such Lonza Facility for the applicable Bulk Product Component(s) during the
most recent manufacturing campaign, after the first half of the campaign, and if
applicable the [***] required for a change over at such facility, averaged over
the most recent [***] events of a change over. As of the Effective Date, the
Parties believe that the "Maximum Capacity" for the applicable manufacturing
suites at the Lonza Facility - assuming uninterrupted campaigns per Bulk Product
Component - is [***] Batches of the Lipase Bulk Product Component, [***] Batches
of the Protease Bulk Product Component, and [***] Batches of the Amylase Bulk
Product Component in one calendar year (with the understanding that, since [***]
are made in the same suite at the Lonza Facility, the "Maximum Capacity" of such
Lonza Facility for such [***] Bulk Product Components is not additive, but
depends on the number of batches of each component manufactured. E.g., according
to the foregoing, and the expected time for a "change over", the Parties
anticipate that a total "Maximum Capacity" of [***] of [***] and [***] of [***]
could be manufactured in a given calendar year. If Altus elects to have more
than one production campaign run for [***] and [***] in a given year, the
maximum number of Batches of each will be reduced due to the additional time
demand for the required changeover(s)).

      1.35 "PRODUCT COMPONENT" means the specific protease, amylase or lipase
proteins as described in EXHIBIT A of this Agreement (as applicable).

      1.36 "PROJECT PLAN" means the plan attached as part of this Agreement,
which sets forth the Parties agreed plans and schedule for performing the
technology transfer, equipment and materials purchase, equipment installation
and validation, engineering and validation runs and other related activities as
contemplated by this Agreement for preparing the Lonza Facilities to be
qualified for commercial manufacture of Bulk Product Components. The Parties
agree to review the Project Plan regularly and update it in writing as needed to
reflect the then-current plans and schedule.

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       5.

<PAGE>

      1.37 "PURCHASE ORDER" shall mean an Altus purchase order, in the form
typically used by Altus, a copy of which (as of the Effective Date) is attached
as Exhibit J.

      1.38 "QUALITY CONTROL PROCEDURES" has the meaning set forth in Section
4.1.

      1.39 "RECEIVING PARTY" has the meaning set forth in Section 8.1.

      1.40 "REGULATORY APPLICATION" means, for a particular country or
regulatory jurisdiction, an application or other filing by Altus or its
Affiliate or licensee for Regulatory Approval, or for approval or permission to
conduct human clinical trials (as applicable), by the applicable Regulatory
Authority regarding a Bulk Product Component and/or Final Product.

      1.41 "REGULATORY APPROVAL" means, for a particular country or regulatory
jurisdiction, all approvals from the applicable Regulatory Authority required
for the commercial marketing or sales of a pharmaceutical product in such
country, along with satisfaction of any related applicable regulatory
requirements.

      1.42 "REGULATORY AUTHORITY" means the FDA in the United States, or the
equivalent regulatory authority or entity having the responsibility,
jurisdiction, and authority to approve the manufacture, use, importation,
packaging, labeling, marketing and sale of pharmaceutical products in any other
country or regulatory jurisdiction.

      1.43 "REGULATORY STANDARDS" has the meaning set forth in Section 3.2.

      1.44 "TECH TRANSFER AGREEMENT" means that certain Technology Transfer
Agreement between the Parties dated April 11, 2006.

      1.45 "TECHNOLOGY TRANSFER PLAN" means the written summary that is attached
as Exhibit D of this Agreement, which sets forth the specific technology
transfer activities to be completed by the Parties.

      1.46 "TERM" means the term of this Agreement, as set forth in Section 9.1.

      1.47 "THIRD PARTY" means any entity or individual other than Altus and
Lonza and the Affiliates of either Party.

      1.48 "TRANSFER PRICE" means, with respect to a particular Batch of Bulk
Product Component included in Bulk Product supplied by Lonza to Altus hereunder,
the amount that Altus shall pay Lonza for supply of such Bulk Product to Altus
as set forth in Section 5.1.

      1.49 "TRANSPORT COSTS" has the meaning set forth in Section 2.8.

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       6.
<PAGE>

                                    ARTICLE 2

                   TECHNOLOGY TRANSFER AND PROCESS VALIDATION

      2.1 COMPLETION OF TECHNOLOGY TRANSFER.

            (a) Under the terms of the prior Tech Transfer Agreement, the
Parties have been engaged in a program of transferring specific technology and
materials relating to the manufacture of Bulk Product Components, to enable the
commencement of manufacturing scale-up and validation by Lonza promptly after
the entry into this Agreement. The Parties shall use [***] to complete the
transfer to Lonza of [***] Altus Manufacturing Technology and Materials, as
determined by Altus and Lonza, all in accordance with Technology Transfer Plan
and as soon as possible after the Effective Date. Lonza shall keep Altus
regularly and fully informed of Lonza's progress in completing the technology
transfer and the other related activities as specified in Section 2.3 through
2.6 below, including permitting appropriate Altus employees or representatives
to visit and inspect the Lonza Facilities and as needed the Lonza Development
Site in connection with conducting such work. Except as otherwise provided in
Section 3(ii) of the Amendment No. 1 of the Letter of Intent, each Party shall
bear its own costs in effecting and completing such technology transfer. Lonza
acknowledges that Altus has already paid to Lonza a total of CHF [***]
compensation for Lonza's efforts in effecting the technology transfer and
implementation and in conducting the process limits evaluation under Section
2.5.

            (b) Under the Tech Transfer Agreement, the Parties established a
Joint Project Team (the "JPT") to oversee and implement the technology transfer
between the Parties in accordance with the Technology Transfer Plan. The JPT
shall continue in existence, comprised of such number of members of each Party
as shall be mutually agreed by the Parties, until the completion of the
activities contemplated by the Technology Transfer Plan. The JPT shall have the
authority to resolve technical issues that may arise in connection with such
technology transfer activities, and shall have the right to amend or modify as
appropriate the Technology Transfer Plan, but otherwise the JPT shall not have
any authority or ability to modify, amend or waive any of the terms and
conditions of this Agreement. All decisions, if any, by the JPT shall be made by
consensus, with each Party having collectively one vote on the JPT.

      2.2 MASTER BATCH RECORDS AND MANUFACTURING SOPS. At the appropriate time
prior to commencing the validation studies under Section 2.4 below, the Parties
shall meet and establish the specific Master Batch Records, including
Manufacturing SOPs, to be used by Lonza to manufacture each Bulk Product
Component. The specific Manufacturing SOPs shall be based upon the Altus
Manufacturing Technology and the Materials provided by Altus, any applicable
Lonza Technology, and any applicable Manufacturing Inventions. Each of the
Master Batch Records shall contain such items and requirements as typical in the
industry for manufacturing processes applicable to similar bulk pharmaceutical
manufacturing, shall be set forth in a written document signed by both Parties.
As of the Effective Date, the Bulk Specifications for each Bulk Product
Component are in draft form. As soon as practicable, Altus shall modify and

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       7.
<PAGE>

amend such Bulk Specification as appropriate, in consultation and cooperation
with Lonza, and upon the Parties' agreement on the final Bulk Specifications
(which agreement shall not be withheld by Lonza except for good cause), such
final Bulk Specifications shall be attached as Exhibit B of this Agreement. If
appropriate during the Term (such as, to include new Manufacturing Inventions
that are useful to manufacturing Bulk Product Component), the Parties will meet
and agree on appropriate amendments or modifications to the applicable Bulk
Specifications, Manufacturing SOPs and/or the Master Batch Records; the details
of the procedure for amending the Bulk Specifications, Manufacturing SOPs and/or
the Master Batch Records shall be as specified in the Quality Agreement.

      2.3 EQUIPMENT [***] AND INSTALLATION. Lonza undertakes and agrees to
complete [***] the [***], installation and validation, at the Lonza Facility, of
all the equipment set forth on EXHIBIT E of this Agreement (the "Designated
Equipment"). Lonza will use [***] to complete such validation on a schedule that
permits initiation of the manufacturing of the Protease validation Batches (as
discussed in Section 3.5) within the time frame contemplated in the Project
Plan. Altus will use [***] to cooperate with Lonza to assist in Lonza's efforts
to complete such validation as soon as possible. If clean room validation is
necessary, approximately 6 weeks will be required in addition to the initial
time demand. It is understood that the timeline depends on the actual delivery
time of the equipment. Altus will review and sign off on the required documents
relating to such equipment validation, and shall use [***] to complete such sign
off within [***] working days of receipt of the documents and all information
needed for such review and sign off, provided that Lonza has submitted to Altus
drafts of such documents [***] reasonably available. It is understood that such
[***], installation and validation of the Designated Equipment is essential to
enable Lonza to commercially manufacture Bulk Product Components at the Lonza
Facility on behalf of Altus in the manner and within the timelines specified in
this Agreement. Lonza acknowledges that Altus has already paid to Lonza a total
of [***] U.S. dollars [***] to assist in such [***], as contemplated by the
Letter of Intent between the Parties, and that all remaining costs and expenses
of Lonza in acquiring, installing and validating the Designated Equipment shall
be borne and paid for by [***].

      2.4 MANUFACTURING PROCESS VALIDATION. Promptly after the Parties have
agreed on the Master Batch Records, Lonza will commence and conduct certain
validation studies to validate each of the Manufacturing SOPs (including an
engineering manufacturing run for each Bulk Product Component), as described in
EXHIBIT F. The actual detailed protocols for such studies shall be developed by
mutual agreement of the Parties, with Lonza preparing the initial proposed
protocols for review and comment by Altus. Lonza shall disclose to Altus in
written reports all results of such validation studies and all other
deliverables as required under Exhibit F. Lonza will, [***] provide all
documents listed in Section 2.16 of the Quality Agreement in English. If the
translation of a significant volume of additional documents (such as SOPs that
are not Altus specific, and hand written text in executed Batch Records) is
required, Lonza's may, at its discretion, [***] [***] for such translation to
Altus on a [***] basis. In addition, if requested by Altus, Lonza will provide
translation into Japanese or any other language (other than English) of any
documents relating to manufacture of Bulk Product

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       8.
<PAGE>

Component, for regulatory or any other purposes, and the [***] for any such
additional translations shall be borne by [***].

      2.5 PROCESS LIMITS EVALUATION. Lonza will commence and conduct the process
limits evaluation studies as set forth in EXHIBIT G, in accordance with the time
schedule set forth in such Exhibit G, which studies are intended to further
define process parameter limits in order to establish a reproducible process for
the manufacture of each Bulk Product Component. Lonza shall disclose to Altus in
written reports all results of such evaluation studies and all other
deliverables as required under Exhibit G.

      2.6 STABILITY STUDIES AND REPORT. Lonza shall conduct stability studies on
each Product Component manufactured by Lonza hereunder, in accordance with the
study protocols set forth in EXHIBIT H of this Agreement, such protocols to be
established by the Parties in good faith prior to Lonza commencing the process
validation campaigns under Section 2.4 above. Lonza shall prepare and deliver to
Altus written reports setting forth the results of the studies, such reports to
be in the form and at the time points described in Exhibit H and all other
deliverables as required under Exhibit H.

                                    ARTICLE 3

                        SUPPLY OF BULK PRODUCT COMPONENTS

      3.1 MANUFACTURE AND SUPPLY. Lonza agrees to manufacture and supply to
Altus the Bulk Product Components conforming to the applicable Bulk
Specifications, in such quantities as ordered by Altus in binding Purchase
Orders submitted to Lonza by Altus under Section 3.2 (but subject to the minimum
purchase commitments in Section 3.3 and to the applicable provisions of Section
3.2) and in accordance with the terms of this Agreement. Lonza shall ensure that
all Bulk Product Component shall be manufactured in accordance with the
applicable Manufacturing SOPs and shall complete the Batch Records for each
Batch. Lonza shall provide to Altus each [***] a written production statement
summarizing all work in process, any deviations from manufacturing process,
expected completion dates for the Batches then being manufactured, and total
amounts of each specific Bulk Product Component that has been completed, and of
what amounts have a completed a Certificate of Analysis and what amounts remain
for quality testing. Lonza's manufacturing of a particular Batch shall be deemed
completed at such time as the Batch is released by Lonza after its QC and QA
inspection. Lonza shall use [***] to maximize the yield of Bulk Product
Component in each Batch manufactured.

      3.2 PURCHASE ORDERS; CONFIRMATION.

          (a) To order Batches of Bulk Product Component to be supplied by
Lonza, Altus shall provide to Lonza written binding Purchase Orders, specifying
the type(s) and Batches of Bulk Product Component(s) ordered, delivery
destination and the requested delivery dates for the particular Batches. In any
such Purchase Order, the quantity of Bulk Product Component ordered shall be in
multiples ([***]) of [***] Batch of the Bulk Product Component (except as
otherwise provided in Section 6.2). No

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       9.
<PAGE>

later than [***] each year during the Term of this Agreement (and except as
otherwise provided in Section 3.5(f)), Altus shall submit a written Purchase
Order (the "Annual Order") ordering the Batches of each Bulk Product Component
to be manufactured and supplied by Lonza and purchased by Altus in the following
year, and such Purchase Order shall be binding on the Parties and shall conform
to the forecasting and ordering limitations in Section 3.4 below. Promptly after
the submission of an Annual Order, the Parties shall meet and discuss in good
faith and agree reasonably on the timing and schedule of the manufacturing
campaigns to be conducted by Lonza during the following year to manufacture and
deliver the total number of Batches ordered in such Annual Order and on the
delivery schedule for each of the Batches resulting from such manufacturing
campaign (such agreed schedule for a particular calendar year, the
"Manufacturing Schedule", and as such schedule may be modified as provided
elsewhere in the Agreement). Such Manufacturing Schedule would include the
expected release and delivery by calendar quarters of the Batches ordered for
the calendar year, for each Bulk Product Component. It is expected that, unless
otherwise agreed by the Parties, Lonza would conduct, for each Bulk Drug
Component, one manufacturing campaign to manufacture the total number of Batches
of such Bulk Drug Component ordered in the Annual Order, and that the Batches
would be delivered to Altus on a regular schedule promptly after particular
Batches, made in the campaign, had completed the required testing to complete
release and execution of the accompanying Certificate of Analysis. The Parties
also agree that, if commercially reasonable given Altus' needs, the
manufacturing campaign for Batches of a particular Bulk Product Component
ordered under an Annual Order (or an additional Purchase Order submitted as
contemplated below) may extend beyond the end of the applicable calendar year
into the following year, and the term of such campaign would be as set forth in
the agreed Manufacturing Schedule applicable to such campaign. Unless otherwise
agreed by Altus, a Batch shall not be delivered to Altus more than [***] after
such Batch completed manufacture by Lonza (release date); it is understood that
Lonza may desire to manufacture and stockpile a reasonable number of Batches
early, and that to do so Altus would need to waive the foregoing requirement,
which Altus agrees to do to the extent reasonable and provided that the Batches,
when subsequently delivered by Lonza, will have adequate remaining shelf life.

            (b) After having submitted the Annual Order applicable to a
particular year, Altus shall also have the right, if Altus determines that its
requirements for Bulk Drug Component(s) exceed the amounts covered by such
Annual Order, to submit one or more additional Purchase Orders ordering
additional Batches of a particular Bulk Product Component, to be manufactured
and supplied by Lonza during such year, but subject to the following provisions.

                  (i) If such an additional Purchase Order ordering a particular
Bulk Drug Component is submitted at least [***] prior to the end of the
scheduled manufacturing campaign for such Bulk Drug Component in such calendar
year, and provided that such Purchase Order is submitted prior to [***], then
such Purchase Order shall be binding on the Parties, and Lonza shall extend
(subject to the other provisions of this subclause (b)(i)) such manufacturing
campaign to manufacture and supply to Altus the additional Batches of such Bulk
Drug Component as ordered in such additional Purchase order, but provided that,
for clarity, Lonza shall be obligated to manufacture and deliver, during such
manufacturing campaign, only such number of additional Batches under such
Purchase Order (unless otherwise agreed by the Parties in writing) to the extent
that such number, when added to the total number of Batches of Bulk Product
Components that have already been ordered by Altus for manufacture during such
calendar year at the applicable Lonza Facility, equals but does not exceed the
Maximum Capacity for such Lonza Facility. It is understood that for Lonza to
extend a manufacturing campaign pursuant to a Purchase Order submitted by Altus
under this subclause (b)(i), Lonza will need to have in its [***] all of the
[***] needed to conduct the manufacture of the Batches covered by such Purchase
Order. Each of Lonza and Altus shall use [***] to obtain the needed supplies of
[***] to manufacture the Batches covered by such an additional

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       10.
<PAGE>

Purchase Order, prior to the date(s) that such materials would be needed by
Lonza to conduct, as part of the extended campaign, the manufacturing of such
Batches. To the extent that Lonza does not have in its possession, at the
initiation of or at any time during a manufacturing campaign that has been
extended by Altus as provided in this subclause (i), [***] needed to continue to
manufacture Batches under such additional Purchase Order submitted to extend the
campaign, but provided that Lonza (and Altus, with respect solely to any such
[***] that Altus is to supply to Lonza) have used [***] to obtain all such
[***], then Lonza would not [***] the additional Batches so ordered until [***],
and would have the right [***] upon [***] of [***], but provided that the
Parties will then discuss in good faith, as provided in subclause (iii) below,
the later initiation of a new [***] to [***] all the Batches under such Purchase
Order at such time as all [***] are [***] by Lonza, and Lonza shall [***] [***]
to obtain [***] as soon as possible and to initiate such new campaign [***].
Further, Altus understands and agrees that the Manufacturing Schedule may need
to be modified to change the schedule for manufacturing another Bulk Product
Component at such Lonza Facility, if such additional ordered Batches cause the
manufacturing campaign, as extended to accommodate the added Batches, to
interfere with the commencement of the manufacturing campaign for such other
Bulk Product Component. Promptly after submission of an additional Purchase
Order under this subclause (b)(i), the Parties shall meet and modify the
Manufacturing Schedule to reflect the schedule and timing of manufacturing and
delivery of such additional ordered Batches and any required modification to the
schedule for manufacturing such other Bulk Product Component (if applicable) at
the Lonza Facility.

                  (ii) After [***] Altus would like to extend an ongoing
manufacturing campaign for a particular Bulk Drug Component in a particular
calendar year, beyond the then-scheduled completion of such campaign under the
applicable Manufacturing Schedule, in order to have Lonza manufacture and
deliver additional Batches (beyond those covered by the existing Purchase
Order(s)) of such Bulk Drug Component, Altus may submit an additional Purchase
Order covering such additional Batches. In such event, the Parties shall meet
and discuss in good faith modifying the Manufacturing Schedule so that Lonza
would extend such manufacturing campaign, and/or if [***], initiate later a new
manufacturing campaign, as needed to manufacture the Batches (or Kgs, as
applicable) of such Bulk Drug Component ordered under such additional Purchase
Order. Lonza shall [***] to [***] the manufacturing and delivery of

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       11.
<PAGE>

as much of such additional Altus Purchase Order submitted under this subclause
(b)(ii) as is [***], given Lonza's [***] at the applicable Lonza Facility.

                  (iii) If an additional Purchase Order ordering a particular
Bulk Drug Component is submitted under this Section 3.2(b) after [***] of the
manufacturing campaign conducted by Lonza during the same calendar year for
manufacturing the Batches of such Bulk Drug Component ordered in the applicable
Annual Order, then the Parties shall meet and discuss in good faith the schedule
for Lonza to initiate a new manufacturing campaign as needed to manufacture the
Batches (or Kgs, as applicable) of such Bulk Drug Component ordered under such
additional Purchase Order, and subject also to the terms of Section 3.5 with
respect to reservation of the Facilities by Altus. Lonza shall [***] to make the
appropriate Facility available at an appropriate time during such year to
reinitiate and conduct the needed manufacturing campaign to [***] of such Bulk
Drug Component ordered under such additional Purchase Order, and provided that,
for clarity, in no event shall Lonza be obligated to agree to manufacture and
deliver, based on any such submitted Purchase Order, any additional Batches
under such Purchase Order (unless otherwise agreed by the Parties in writing) to
the extent that such number, when added to the total number of Batches of Bulk
Product Components that have already been ordered by Altus for manufacture in
during such calendar year at the applicable Lonza Facility, exceeds the Maximum
Capacity for such Lonza Facility. Further, Altus agrees that, if in order to
initiate a new manufacturing campaign to manufacture additional Bulk Product
Components ordered by Altus under this subsection 3.2(b)(ii), Lonza must conduct
a [***] of the Lonza Facility, then Altus shall pay to Lonza a [***] equal to:
(A) the [***] for such Lonza Facility, which equals CHF [***] per day for [***]
manufacturing suite, and CHF [***] per day for the [***] suite, times (B) the
total number of [***] (but not in any event to exceed [***] [***]) actually
required by Lonza to conduct such [***], but provided that Lonza uses [***] to
minimize such number of days required to complete the [***]. The Parties shall
agree on the [***] to be owed by Altus in such event, prior to Lonza initiating
such [***] and in connection with the Parties' agreement on the scheduling of
such additional manufacturing campaign. Upon the Parties' agreement in writing
as to the scheduling of such additional manufacturing campaign (and including
any required adjustment to the timing and schedule for the manufacturing of
another Bulk Product Component at such Lonza Facility during such calendar year,
if applicable), the Parties shall agree in writing on the modified Manufacturing
Schedule to reflect such agreement, and such additional Purchase Order submitted
by Altus shall be binding on the Parties, and Lonza shall manufacture the
additional Batches of such Bulk Drug Component as ordered in such additional
Purchase Order and shall supply such Batches to Altus in accordance with an
agreed delivery schedule.

            (c) Lonza must [***] and shall be [***] each Purchase Order
reflecting an Annual Order provided by Altus in accordance with the terms of
this Agreement. As to any additional Purchase Order placed by Altus pursuant to
Section 3.2(b), Lonza must [***] and shall be [***] each such additional
Purchase Order to the extent that such Purchase Order is specified to be [***]
on the Parties under the applicable terms of Section 3.2(b) or 3.5. Purchase
Orders for Bulk Product Components submitted by Altus shall reference this
Agreement and shall be governed

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       12.
<PAGE>

exclusively by the terms contained herein. Any provision in any purchase order,
invoice, or similar document furnished by Altus or Lonza that is in any way
inconsistent with the terms and conditions set forth in this Agreement is hereby
rejected, unless expressly provided otherwise in writing by the Parties.

      3.3 MINIMUM PURCHASE COMMITMENTS.

          (a) ENGINEERING, VALIDATION AND INITIAL COMMERCIAL BATCHES. Subject
to the other terms and conditions of this Agreement, Altus hereby makes a
binding commitment to submit Purchase Orders comprising Annual Orders for the
purchase of at least the minimum number of Batches of each Bulk Product
Component as set forth below during 2007 and 2008:

<TABLE>
<CAPTION>
 YEAR                LIPASE                       AMYLASE                    PROTEASE
-------      ------------------------     -------------------------    ---------------------
<S>          <C>                          <C>                          <C>
[***]        [***] Engineering Batch       [***] Engineering Batch      [***] Engineering Batch
             [***] Validation Batches      [***] Validation Batches     [***] Validation Batches
             [***] Commercial Batch        [***] Commercial Batch       [***] Commercial Batch

[***]        [***] Commercial Batches      [***] Commercial Batches     [***]
</TABLE>

      The binding Annual Order for [***] shall be submitted no later than [***],
and for [***] shall be submitted no later than [***]. In the event that Altus
does not submit an Annual Order for [***] or [***] (as applicable), containing
the respective numbers set forth in the above table by the above mentioned
dates, the numbers as set out in the table above shall be treated as the Annual
Order for the applicable calendar year. Lonza commits to commence the validation
Batches of the Protease, Lipase and Amylase Bulk Product Component as provided
in the agreed Project Plan attached as Exhibit K. Lonza acknowledges and agrees
that the Manufacturing Schedule for manufacturing Batches in [***] under the
Annual Order submitted in [***] may need to be adjusted by Altus to accommodate
changes in the manufacturing process, and Lonza agrees to reasonable adjustments
as requested by Altus.

            (b) SUBSEQUENT YEARS' COMMERCIAL BATCHES - [***] THROUGH [***]. For
years [***] through [***], Altus projects that it will submit Purchase Orders
for the purchase of approximately the number of Batches of each Bulk Product
Component as set forth below for each year:

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       13.
<PAGE>

<TABLE>
<CAPTION>
   YEAR                LIPASE                        AMYLASE                     PROTEASE
----------     ------------------------     --------------------------    -------------------------
<S>            <C>                           <C>                          <C>
    [***]      [***] Commercial Batches      [***] Commercial Batches     [***] Commercial Batches

    [***]      [***] Commercial Batches      [***] Commercial Batches     [***] Commercial Batches

    [***]      [***] Commercial Batches      [***] Commercial Batches     [***] Commercial Batches

    [***]      [***] Commercial Batches      [***] Commercial Batches     [***] Commercial Batches
</TABLE>

      Lonza acknowledges that the above Batch numbers are good faith,
non-binding estimates, and Altus' actual purchases of Batches of any particular
Bulk Product Component shall be based on Purchase Orders submitted in compliance
with Section 3.2 and 3.4. The binding Annual Order for each of [***] shall be
submitted no later than [***] the prior year.

      3.4 FORECASTS FOR BULK PRODUCT COMPONENT ORDERS. For [***], and for each
calendar year thereafter during the Term, Altus shall provide Lonza with good
faith rolling forecasts of its expected orders of each of the Bulk Product
Components to be manufactured and supplied by Lonza during such calendar year
(each, a "Forecast"). The first such Forecast for a particular calendar year
shall be submitted no later than [***] prior to beginning of such year, and
Altus shall submit to Lonza an updated Forecast as of the beginning of the [***]
calendar quarters of the year prior to such particular calendar year. Each such
Forecast shall constitute Altus' [***] estimates of its expected orders for each
of the Bulk Product Components during such year, as of the date of the Forecast.
None of the Forecasts shall constitute commitments (binding or otherwise) to
order amounts of Bulk Product Component; provided, however, that the total
quantity of a particular Bulk Product Component ordered by Altus in the Annual
Order submitted under Section 3.2(a) for a particular year (through the Annual
Order submitted in [***]) may not (unless the Parties otherwise agree) vary
(either up or down) by more than: (a) [***] from the amounts of such Bulk
Product Component forecasted to be ordered for such year in the Forecast
covering such year submitted by Altus by the beginning of the [***] of the
previous year; or (b) [***] from the amounts of such Bulk Product Component
forecasted to be ordered for such year in the Forecast covering such year
submitted by Altus by the beginning of the [***] of the previous year.
Commencing with the Annual Order submitted in [***], and each Annual Order
thereafter, the total quantity of a particular Bulk Product Component ordered by
Altus in the Annual Order submitted under Section 3.2(a) for a particular year
(during such period) may not vary (either up or down) by more than: (a) [***]
from the amounts of such Bulk Product Component forecasted to be ordered for
such year in the Forecast covering such year submitted by Altus by the beginning
of the [***] of the previous year; or (b) [***] from the amounts of such Bulk
Product Component forecasted to be ordered

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       14.
<PAGE>
for such year in the Forecast covering such year submitted by Altus by the
[***] of the previous year.

      3.5 FACILITIES RESERVATION.

          (a) Altus shall have the right to reserve, during a particular
calendar year, the applicable Lonza Facility (and resources associated with such
facility) as needed for Lonza to produce a specified number of Batches of a
particular Bulk Product Component, such reservation(s) to be made and
implemented according to the following terms and conditions: If Altus desires to
so reserve an applicable Lonza Facility (and related resources) during a
particular calendar year, Altus shall provide to Lonza a facilities reservation
notice (a "Reservation Notice") no later than [***] of the prior year. Such
Reservation Notice shall specify the number of Batches of each particular Bulk
Product Component(s) for which Altus would like to reserve the applicable Lonza
Facility manufacturing time during the following calendar year (such reservation
to be above and beyond the Lonza Facilities time needed to manufacture all the
Batches covered by the Annual Order for such year). Promptly after Lonza's
receipt of a Reservation Notice, the Parties shall meet and [***] and [***] on
the time frame, during the specified calendar year, during which Lonza shall
reserve the applicable Lonza Facility for Altus, including [***] on [***] (based
on Lonza's experience in manufacturing Batches) that will need to be reserved to
accommodate such manufacturing, and the commencement date of such reservation
(collectively, the "Reservation Period" applicable to such Reservation Notice).
It is anticipated that, unless the Parties otherwise agree based on [***], the
Reservation Period shall be scheduled to be near the [***] the [***]. Lonza
covenants and agrees that, except as otherwise provided below, and subject to
the other terms of this Section 3.5, Lonza shall reserve adequate manufacturing
time and resources in the appropriate Lonza Facility in order to manufacture,
during the applicable calendar year prior to the end of such year, the Batches
specified in a particular Reservation Notice.

          (b) If Altus has submitted a Reservation Notice as to a particular
calendar year, Altus shall update such Reservation Notice in writing if at any
time Altus determines that it no longer needs to reserve the total amount of
manufacturing time as specified in the original Reservation Notice. Such update
shall specify the total number of Batches of the applicable Bulk Product
Component(s) for which Altus at that time requires Facilities manufacturing
capacity to be reserved by Lonza. Such updated notice shall then constitute the
"Reservation Notice" for such calendar year, unless and until a subsequent
updated notice is submitted by Altus under this subsection (b). Promptly after
Altus' submission of any such updated Reservation Notice, the Parties shall meet
and agree in good faith on the appropriate modified Reservation Period
applicable to such updated Reservation Notice, as contemplated in subsection (a)
above.

          (c) If Altus has submitted a Reservation Notice for a calendar year,
and during such year Altus desires to have Lonza manufacture Batches of the
applicable Bulk Product Component(s) within the total number of Batches covered
by such Reservation Notice (that is, for which manufacturing capacity has been
reserved by Lonza under the terms of subsection (a) above based on such
Reservation Notice), then

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       15.
<PAGE>

Altus shall submit a Purchase Order covering the specific number of Batches to
be manufactured and supplied by Lonza, and such Purchase Order shall be binding
on Lonza and Altus. Lonza shall manufacture such Batches of the applicable Bulk
Product Component(s) covered by such Purchase Order commencing at the beginning
of the applicable Reservation Period (or at such other time as agreed to by the
Parties in writing). If, based on Purchase Order(s) submitted by Altus under
this subsection (c), Lonza manufactures Batches covered by such Purchase
Order(s), the amount of such manufacturing time that occurs during the
applicable Reservation Period shall automatically be deducted from the
Reservation Period, and the Reservation Period shall be accordingly reduced to
the time period (if any) remaining after deducting such actual period of
manufacturing such Batches from such original Reservation Period.

          (d) If Altus has submitted a Reservation Notice for a calendar year,
and by the date that is [***] prior to the commencement of the Reservation
Period applicable to such Reservation Notice (or such other time point as
applicable under subsection (f) below), Altus has not submitted [***] Purchase
Orders covering Batches of Bulk Product Component to be manufactured by Lonza
using the manufacturing capacity reserved by Lonza based on such Reservation
Notice, then Altus must commit in writing by such date either: (i) to pay the
applicable "Facilities Reservation Fees" for the amount of manufacturing
capacity (if any) that goes unused in such Reservation Period, as calculated in
subsection (e) below; or (ii) to cancel the reservation of capacity covered by
such Reservation Notice in which case Lonza shall immediately be free from the
reservation, the Reservation Period shall automatically terminate, and Lonza may
use the applicable Facilities for any purpose during such period of time; or
(iii) to cancel the reservation of a specific amount of the capacity covered by
such Reservation Notice, in which case Lonza shall immediately be free from the
reservation as to such amount of capacity (which Lonza may use the applicable
Facilities for any purpose during such period of time), and the Reservation
Period shall automatically be limited to the remaining amount of time (that is,
after excluding such cancelled capacity), and Altus shall pay the applicable
"Facilities Reservation Fees" for the amount of manufacturing capacity (if any)
that goes unused in such shortened Reservation Period, as calculated in
subsection (e) below. If Altus makes an election under subclause (i) or (iii)
above, but subsequently determines that it does not need amounts of the reserved
manufacturing capacity covered by the applicable Reservation Notice, Altus may
give Lonza notice to the effect that it is canceling specified amounts of the
reserved capacity (up to the total remaining Reservation Period), and Lonza may
then utilize such cancelled capacity for any purpose, and shall [***].

          (e) The "Facilities Reservation Fees" payable by Altus, if Altus
elected (as to a particular calendar year) under subclause (d)(i) or (d)(iii)
above to pay such fees as to the applicable Reservation Period, shall be
calculated as follows: (i) the [***] of the applicable Reservation Period (as
such period may have been shortened pursuant to an Altus election under
subclause (d)(iii)) that were not utilized in manufacturing Batches ordered by
Altus and/or other Altus products as provided in subsection (g) below,
multiplied by (ii) CHF [***] per day (for Reservation Periods in [***] and
[***]), or CHF [***] per day for Reservation Periods thereafter. Altus shall
then pay such Facilities Reservation Fees as to the applicable Reservation
Period for

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       16.
<PAGE>

which Altus made such election, within [***] of the end of such Reservation
Period.

          (f) The Parties further agree that, in the event Altus has not
obtained Regulatory Approval in the United States of the Final Product by [***],
or by [***], then in lieu of submitting an Annual Order for orders of Bulk
Product Components in calendar year [***], or [***] (as applicable) as provided
in Section 3.2(a) (and notwithstanding the requirements of Section 3.4, which
shall not apply in this case), Altus may instead submit by [***], or by [***]
(as applicable), a Reservation Notice that reserves manufacturing capacity in
the applicable Lonza Facilities for the amount of time needed to manufacture the
number of Batches of each Bulk Product Component as specified in such
Reservation Notice. Promptly after Lonza's receipt of such Reservation Notice
under this subsection (f), the Parties shall meet and discuss in good faith and
agree on the time frame, during calendar year [***] (as applicable), during
which Lonza shall reserve the applicable Lonza Facility for Altus, including
agreeing on the amount of time (based on Lonza's experience in manufacturing
Batches) that will need to be reserved to accommodate such manufacturing, and
the commencement date of such reservation, which shall be the "Reservation
Period" applicable to such Reservation Notice. It is anticipated that, unless
the Parties otherwise agree based on commercially reasonable business reasons of
Altus, the Reservation Period shall be scheduled to be completed near the end of
[***]. The other provisions above of this Section 3.5 shall apply to a
Reservation Notice submitted under this subsection (f), but with the following
additional requirement: If by the date that is the earlier of (i) [***] before
the commencement of such Reservation Period under this subsection (f), or (ii)
[***], or [***] (as applicable), Altus has not submitted to Lonza a binding
Purchase Order to manufacture Batches of each of the Bulk Components at least
equal to [***] of the number of Batches of each as covered by the Reservation
Notice submitted under this subsection (f), then Lonza may terminate this
Agreement under the terms of Section 11.4.

          (g) Lonza agrees that, to the extent Altus has reserved capacity in
a Lonza Facility by submitting a Reservation Notice, and has not either timely
cancelled such reservation (under subsection (d) above) or used such reserved
manufacturing capacity to manufacture Bulk Product Component, then to the extent
such Lonza Facility is usable to manufacture another product for Altus, Lonza
will if requested by Altus use such Lonza Facility during the applicable
Reservation Period (or portion thereof) to manufacture requested amounts of such
other product, at a [***] to be [***] the Parties [***]. In such event, Altus
would be responsible for transferring [***] needed by Lonza to manufacture such
product, and Altus would pay Lonza [***] of such technology transfer as agreed
by the Parties.

      3.6 DELIVERY. For each Purchase Order submitted by Altus in accordance
with the terms of this Agreement, Lonza shall deliver to Altus or Altus's
designee, at the delivery destination and by the delivery date specified in such
Purchase Order (or such other delivery date as agreed by the Parties), the
specified quantity (or such lesser amount as required pursuant to the terms of
Section 3.2(b) if applicable) of each Bulk Product Component conforming to the
applicable Bulk Specifications and manufactured in accordance with cGMP and
other requirements of this Agreement. At least [***] days prior to Lonza's
delivery of Bulk Product Component satisfying a particular Purchase

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       17.
<PAGE>

Order, Lonza shall provide to Altus a Delivery Confirmation identifying the
specific date on which Lonza shall deliver such Bulk Product Component at the
specified destination, which confirmation shall set forth the Altus Purchase
Order number and Lonza's Confirmation number to which that delivery corresponds.
Lonza shall immediately report to Altus the occurrence of any event within or
beyond its control which is likely to affect delivery of any order of Bulk
Product Component; the giving of such notice shall not otherwise excuse Lonza's
performance hereunder. Lonza shall provide to Altus the documents described in
Section 4.3 with each delivery of Bulk Product Component.

      3.7 ORDER CANCELLATIONS. Altus may not cancel any Purchase Order, except
as otherwise provided in Article 11.

      3.8 ENGINEERING AND VALIDATION BATCHES.

          (a) ENGINEERING BATCHES. The Annual Order that Altus shall submit by
[***] (for delivery in [***]) shall include a binding order for [***]
engineering Batch of each Bulk Product Component, and Lonza shall manufacture
and supply to Altus such engineering Batches in accordance with this Agreement.
However, for the avoidance of doubt, Lonza will be under no obligation to meet
the Bulk Specifications for such engineering Batches, but Lonza agrees to [***]
[***] such Bulk Specifications. If any such engineering Batch for a particular
Bulk Product Component has [***] (e.g., [***]), then at Altus' request Lonza
shall manufacture and supply to Altus another engineering Batch in accordance
with this Agreement for such Bulk Product Component, at Altus' cost. Lonza may
elect, at their sole discretion, to manufacture and supply to Altus further
engineering Batch(es) in accordance with this Agreement for such Bulk Product
Component, which manufacturing and supply will be at [***].

          (b) VALIDATION BATCHES. The Annual Order that Altus shall submit by
[***] (for delivery [***]) shall also include purchase orders for a total of
three [***] validation Batches for each of the [***] Bulk Product Components.
The Parties shall mutually agree in good faith on appropriate success criteria
for the validation Batches for each Bulk Product Component. If a particular
validation Batch supplied by Lonza pursuant to such purchase order fails to meet
such agreed criteria, appropriate representatives from each Party shall meet and
discuss and seek to determine the causes of such Batch having failed to meet
such criteria and shall cooperate diligently to try to find a solution to such
causes, and Lonza shall [***] [***] any such problems [***]. Depending on what
was the cause of such failure to meet the criteria, the Parties shall agree in
good faith on how the Parties [***] for the [***] manufacturing needed to
complete the validation runs, in compliance with the following: If [***] caused
the failure, then Lonza will [***] the failed Batches [***] ([***] for [***] and
the [***]). [***] the applicable Batch failed to meet such criteria for no
assignable fault, then Lonza will [***] the failed Batch with [***] for [***] of
the [***], and [***] for [***] of the replacement Batch. [***], Lonza shall
[***] manufacture and supply of [***] [***] Batches for the particular Bulk
Product Component [***], and [***] such time [***] has [***] delivered to Altus
[***] Batches of such Bulk Product Component that meet the validation criteria.
Each such validation Batch

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       18.

<PAGE>

supplied by Lonza shall meet the applicable Bulk Specifications and shall be
suitable for commercial use.

      3.9 [***] OF SUPPLY. Lonza shall not [***] for the [***] at the [***] from
any [***] to the extent that such [***] purchase orders, when taken together
with any other orders from [***] for goods to be manufactured at the Lonza
Facility, would [***] Lonza's ability to fulfill on a timely basis all Purchase
Orders of Altus in accordance with their terms. If [***] any [***] to the [***]
will [***] that such [***], if [***] to the [***], are [***] to the [***] of
[***] under this Agreement.

      3.10 SHORTFALLS IN SUPPLY.

          (a) If Lonza fails to deliver to Altus on a timely basis, and
provided that such failure is not caused by the late delivery by Altus of [***]
that Altus is responsible for providing to Lonza under the terms of
Section 3.12, the full amount of Bulk Product Component ordered under any
Purchase Order submitted under Section 3.2 (as such quantities ordered may be
limited under subsection 3.2(b)), Lonza [***] such failure [***], and Lonza also
[***] with regular (at least [***], or [***] if [***] by [***]) and [***]
reports on the status of its efforts, and the [***] date that [***], to cure
such [***] by delivering the required amounts of Bulk Product Component on
order. If such failure to delivery on a timely basis amounts of Bulk Product
Component on order under a Purchase Order remains uncured by the date [***] the
scheduled delivery date, then Altus may purchase from a Third Party any such
amounts of such Bulk Product Component that remain on backorder. If Altus does
so it shall give Lonza written notice thereof, and the relevant Purchase Order
for such amounts shall be deemed canceled as to the amounts that were not
previously delivered by Lonza, and Altus shall not be obligated to accept the
delivery thereafter of such amounts under such Purchase Order (but Lonza may use
any such amounts of the Bulk Product Component manufactured prior to such notice
from Altus to fulfill future Purchase Orders by Altus of such Bulk Product
Component so long as such amounts of Bulk Product Component have an appropriate
period of shelf life remaining as of the time of delivery to Altus to fulfill
such subsequent Purchase Orders), and Lonza shall at that point not be obligated
to continue to fulfill such amounts of Batches that are on order but are past
their delivery dates (but will remain fully obligated to manufacture and supply
on a timely basis all other amounts of Bulk Product Component ordered by Altus
under the terms of this Agreement). Lonza's obligation under this Section
3.10(a) to cure a failure to deliver amounts of Bulk Product Component ordered
under any Purchase Order submitted under Section 3.2 shall terminate at the end
of the calendar year following the year in which such failure occurred, provided
Lonza has used best efforts to cure such failure prior to such date.

          (b) Upon the occurrence of any [***] (as defined in subsection (c)
below), the Parties shall meet immediately and discuss in good faith all
appropriate actions to remedy and cure the [***]. In any event Lonza shall use
[***] to cure the [***], by delivering to Altus all amounts of Bulk Product

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      19.
<PAGE>
Components under [***] Purchase Orders of Altus to the extent such amounts have
not been delivered by the scheduled delivery date(s) under the applicable
Manufacturing Schedule. If Altus reasonably determines that it is unlikely that
Lonza will be able to completely cure a [***] within [***] days of the
occurrence of such [***], or in any event if such [***] is not fully cured
within such [***] day period, then Altus will be relieved of its obligation to
purchase the binding commitments for orders of Bulk Product Component as
provided in Section 3.2 and may immediately fulfill its requirements of the
applicable Bulk Product Component from other qualified manufacturers, to the
extent [***] due to [***] or other failure to deliver on a timely basis Bulk
Product Component ordered by Altus, but with the understanding that Altus [***]
to order and purchase such amounts of Bulk Product Component to the extent
needed to [***] for the Bulk Product Component and that Lonza can demonstrate to
Altus' [***] Lonza [***] and supply [***] such amounts in conformance with all
other provisions of this Agreement.

          (c) As used in the above Section 3.10(b), the term "Supply Failure"
means that any of the following has occurred (regardless of whether a Force
Majeure event has caused any such failure):

               (i) Lonza has failed to supply, by the delivery date in the
applicable Manufacturing Schedule, at least [***] of the amount of any
particular Bulk Product Component, ordered by Altus under a binding Purchase
Order that conforms to the requirements of this Agreement, that was supposed to
be delivered by such date under such Manufacturing Schedule, and such failure is
not cured [***] of such delivery date; or

               (ii) as a result of failures by Lonza to supply, by the
applicable delivery dates in the applicable Manufacturing Schedule, amounts of
any particular Bulk Product Component ordered by Altus in one or more binding
Purchase Orders that conform to the requirements of this Agreement, there exists
at a [***] a [***] of such Bulk Product Component (i.e., amounts of such Bulk
Product Component ordered in submitted Purchase Orders for which [***] of [***]
has not [***] after the scheduled delivery dates under the applicable
Manufacturing Schedule) that exceeds [***] of the total amount of orders by
Altus for such Bulk Product Component for the then-current calendar year.

For purposes of this definition, delivery of Defective Product shall be deemed a
failure to supply Bulk Product Component in a timely manner hereunder.

      3.11 [***].

          (a) Lonza acknowledges that Altus is depending on Lonza achieving at
least a [***] (in kilograms per Batch) of each Bulk Product Component, in order
to meet its needs of Final Product. For Batches manufactured prior to the
Parties agreement (under Section 6.2(b) to convert to per kilogram Transfer
Prices), if the average size (in kilograms per Batch) of the Batches of a
particular Bulk Product Component that were manufactured by Lonza during a
particular campaign (as calculated just prior to the end

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      20.
<PAGE>

of such manufacturing campaign) and shipped by Lonza to Altus is less than the
applicable of the following minimums of kilograms per Batch of the applicable
Bulk Product Component: (x) [***] kilograms per Batch if such Bulk Product
Component is lipase; (y) [***] kilograms per Batch if such Bulk Product
Component is amylase (without dextrin); and (z) [***] kilograms per Batch if
such Bulk Product Component is protease, then the Parties shall proceed as
provided in subclause (b) and (c) below, as applicable.

          (b) Lonza shall determine, as to the particular Bulk Product
Component for such it did not meet the above required minimum average yield
during the particular campaign, the total amount (in kilograms) of the
shortfall, equal to: (i) the expected minimum yield in kilograms (as provided in
subclause (x), (y) or (z) above as applicable) multiplied by the total number of
Batches in such campaign, minus (ii) the actual total number of kilograms of
such Bulk Product Component resulting from such campaign (meeting the applicable
Bulk Specifications and delivered to Altus), which amount shall be the "Yield
Shortfall" for such campaign. If such Yield Shortfall is more than [***] of the
actual average yield (in kilograms) of such Bulk Product Component for a Batch
during such campaign, then Lonza will extend such manufacturing campaign for
such Bulk Product Component, and shall manufacture and deliver to Altus, at
[***] [***] and [***] except for the [***] of [***] (which will be paid for by
[***]), such number of additional Batch(es) of such Bulk Product Component as
needed to manufacture and deliver to Altus at least the amount of kilograms of
such Bulk Product Component equal to such Yield Shortfall. To the extent that
such manufacturing yields additional kilograms of such Bulk Product Component
(i.e., beyond the Yield Shortfall), then Altus will purchase such additional
kilograms at a reasonable time, at a cost equal to the per Batch Transfer Price
then applicable, multiplied by the fraction equal to the ratio of such
additional kilograms divided by the required minimum per Batch yield (in
kilograms) for such Bulk Product Component (as set forth in subclauses (x), (y)
or (z) above as applicable).

          (c) If such Yield Shortfall is less than [***] of the actual average
yield (in kilograms) of such Bulk Product Component for a Batch during such
campaign, then Lonza shall not be obligated to extend the manufacturing campaign
but shall [***] for such Bulk Product Component supplied during such campaign a
[***] to reflect the shortfall.

          (d) Lonza shall in any event [***] to maximize the yield of Bulk
Product Component in each Batch manufactured under this Agreement. For clarity,
the above minimum yield provisions shall not apply to [***], but Lonza
understands and agrees that achieving [***] is [***] for [***], such yields to
be [***] in the [***] as discussed in Section 3.8(b) (with the expectation that
such [***] will be approximately [***] of the [***] for each Bulk Product
Component as described in Section 3.11(a) above.

      3.12 LABELING AND PACKAGING. Lonza shall label and package each Bulk
Product Component to be supplied in accordance with the applicable Manufacturing
SOPs, Altus' directions and Applicable Law applicable to pharmaceutical products

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       21
<PAGE>

shipped in bulk, for shipment to Altus or to one or more fill/finish
manufacturers designated by Altus. Altus shall be responsible for developing the
design and content for the label and package inserts. Upon Altus's request,
Lonza shall assist Altus in developing the design and content for such label and
package inserts, and shall provide regulatory support to obtain and maintain all
necessary Regulatory Approvals for such design and content. Lonza shall provide
such assistance and support at no charge to Altus.

      3.13 STORAGE AND HANDLING. Lonza shall store and handle all Bulk Product
Component as required by the applicable Manufacturing SOPs, Bulk Specifications,
cGMP, and all established safety practices for the Bulk Product Component.

      3.14 SHIPPING; RISK OF LOSS. All shipments of Bulk Product Component by
Lonza will be made [***] (Incoterms 2000) to the delivery destination specified
in the applicable Purchase Order, and all deliveries shall be in accordance with
the shipping instructions of Altus, including by a common carrier specified by
Altus. Lonza shall pay, on Altus's behalf, [***] incurred by Lonza in shipping
Bulk Product Component (collectively, "TRANSPORT COSTS"), unless Altus provides
otherwise in writing on a Purchase Order. Altus will reimburse Lonza for the
reasonable Transport Costs, [***] by Lonza and Lonza shall, upon Altus's
request, provide written documentation supporting such costs. Except as provided
herein with respect to Defective Product, risk of loss as to Bulk Product
Component shipped to Altus or its designee hereunder shall pass to Altus upon
delivery of such Product to the common carrier at the Lonza Facility where the
Bulk Product Component was manufactured. Lonza shall arrange to insure the
shipment of the ordered Bulk Product Component as specified by Altus.

      3.15 [***]. Lonza shall be responsible for procuring all [***] needed for
manufacturing Bulk Product Components, except as otherwise provided below as to
the [***] material. Altus shall [***] Lonza for [***], except for [***] (which
shall be Lonza's responsibility), acquired by Lonza for use in manufacturing the
Bulk Product Components under this Agreement in amounts and on a schedule
reasonably agreed to by the Parties. It is understood and agreed by Lonza that
Altus (in order to have sufficient [***] on hand at Lonza to manufacture
additional requirements of Bulk Product Components in case sales of the Final
Product exceed Altus applicable forecasts) may require that Lonza purchase and
store [***] than would actually be needed to manufacture the amounts of Bulk
Product Components then on order or forecasted, and Lonza agrees to do so if so
requested, subject to Altus reimbursing the actual purchase price as provided
above. Lonza shall provide Altus with specifications and information regarding
such [***] and the names of the vendors. The costs for the goods paid by Altus
shall be invoiced to Altus [***] (i.e., at [***] to [***] from the supplier).
Such invoice to be provided by Lonza after purchase by Lonza of such materials
on the agreed time schedule, and provided that Lonza delivers to Altus with any
such invoice a copy of the invoice for the purchase of such [***] from the Third
Party supplier. Lonza shall purchase and maintain an inventory of [***] in
amounts [***] to manufacture the Batches of Bulk Product Component expected to
be ordered by Altus (according to the Forecasts) in the coming [***]. Lonza
shall [***] to obtain [***] and [***] to at the [***], and shall keep Altus
regularly and fully informed of the [***] [***]

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       22.
<PAGE>
such [***] and the basis for [***], including using [***] with the vendors to
reduce the [***] for purchase of such [***] below the [***] by the applicable
vendor. The Parties would discuss in good faith and agree on a mechanism [***]
any subsequent [***] in [***] that Lonza may be able to negotiate with the
appropriate vendors. Lonza shall utilize only qualified vendors for purchase of
[***] and consumables as specified in the Quality Agreement, and shall conduct
further audits of vendors as needed or as reasonably requested by Altus. Altus
shall initially be responsible for obtaining and providing to Lonza, [***], the
amounts of [***] needed for Lonza to manufacture Bulk Product Components ordered
by Altus under this Agreement; however, the Parties shall work together in good
faith for Lonza to undertake to manufacture, or to purchase from third party
vendor(s), such needed amounts of [***], at the [***].

      3.16 FACILITIES AND EQUIPMENT. Lonza shall be responsible for allocating
appropriate Lonza Facilities, and for obtaining, installing and maintaining in
such Lonza Facilities all capital equipment, as needed to manufacture the
amounts of Bulk Product Components as ordered by Altus. Lonza shall allocate
sufficient time, effort, equipment and facilities to the program for
manufacturing Bulk Product Components, and shall dedicate and use personnel with
sufficient skills and experience as are required to accomplish the manufacturing
tasks, so as to manufacture and deliver Bulk Product Components on a timely
basis and in accordance with the terms of this Agreement. Lonza shall conduct
its manufacturing efforts under this Agreement in compliance with all Applicable
Laws.

      3.17 RESTRICTION ON COMPETITION. During the Term of this Agreement and for
a period of [***] thereafter Lonza agrees not to perform services or otherwise
undertake manufacturing activities for any potential product, product candidate,
product, or product component that contains a [***] for [***]; however, for
clarity, the foregoing restriction shall not apply to the manufacture, on behalf
of a third party, of a product provided that such third party has provided Lonza
[***] and [***]. Notwithstanding the foregoing, Lonza understands and agrees
that the confidentiality and non-use restrictions under Article 10 continue to
apply with respect to all the Confidential Information of Altus.

      3.18 ALTERNATIVE SUPPLIERS. It is understood and agreed by Lonza that
Altus may establish and qualify one or more other facilities (owned or operated
by an Affiliate or Altus or a Third Party) to manufacture Bulk Product
Components and to obtain a secondary supply of Bulk Product Components, subject
to the following: Altus agrees that, except as otherwise provided below or in
Section 3.10, Altus agrees to purchase from Lonza [***] of its requirements for
Bulk Product Component through the [***] of the Effective Date except that such
limitation shall not apply with respect to product that [***] may be able to
supply, and thereafter Altus would commit to purchase from Lonza at least [***]
of its requirements of Bulk Product Components (or such lesser amount as is
equal to [***] of Lonza's [***] for the Bulk Product Components (in the relative
amounts Altus expects to order during a particular year, and taking into
account, if applicable, the amounts of the other Bulk Product Components that
need to be manufactured and supplied to Altus to meet its requirements), and
provided that such limitation shall not apply with respect to amounts of product
that [***] may be able to supply), given the requirements of Altus for all Bulk
Product Components), and the

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      23.
<PAGE>

remainder could be acquired by Altus from second source(s), subject also to the
following. In addition, Altus may purchase Bulk Product Components from
alternative manufacturers if required by Applicable Law or any Regulatory
Authority. Notwithstanding the foregoing, Lonza acknowledges that if the Final
Product is successful, Altus will need to secure and engage an effective and
capable alternative manufacturer to manufacture one or more of the Bulk Product
Components, and that Altus may need to offer such alternative manufacturer, in
order to secure such manufacturing on commercially reasonable terms, more
manufacturing capacity for a particular Bulk Product Component than would be
permitted by the above commitments. In such case, at Altus' request, Lonza
agrees to discuss in good faith and agree on a [***] in [***] to so engage such
alternative manufacturer. Lonza shall provide [***] and [***] as needed to
effect the [***] for a maximum of two of such alternative manufacturer(s) per
applicable Bulk Product Component, to manufacture the applicable Bulk Product
Component; provided that Altus shall [***] [***] for its [***] providing such
assistance, except in the case where Altus engages an alternative manufacturer
[***] of its supply obligations under this Agreement (in which case such
assistance and cooperation [***]). Completion of such technology transfer shall
have the same meaning as in the Tech Transfer Agreement.

      3.19 INVENTORY. Throughout the Term, Lonza shall maintain in inventory at
the Lonza Facility (or at such other appropriate storage facility owned by Lonza
or its Affiliate as is agreed to by Altus) such amounts of Bulk Product
Component that have been manufactured under binding Purchase Orders but have not
yet been delivered by Lonza. Such inventory shall be maintained and stored in
accordance with the terms of this Agreement and Regulatory Standards, and Lonza
shall fulfill Purchase Orders for Bulk Product Component submitted by Altus out
of such inventory on a "first in, first out" basis. Lonza shall provide to Altus
a monthly report listing the total amounts of each Bulk Product Component stored
by Lonza in its inventory at that time. Lonza shall be responsible for such
inventory of Bulk Product Components until ownership of particular quantity of
Bulk Product Component is transferred to Altus based on fulfillment of an Altus
Purchase Order in accordance with the delivery terms of this Agreement.

      3.20 COMMITMENT TO OPTIMIZE SUPPLY RELATIONSHIP. The Parties acknowledge
and agree that one of the primary goals of this Agreement is to provide for the
efficient ordering, manufacture and supply by Lonza of Altus' requirements of
each of the Bulk Product Components on a timely basis and at a low cost so that
Altus may maximize the return on sale of Final Products, and also that Lonza
achieves a reasonable profit on such manufacturing activity and is able, if
applicable, to maximize the utilization of the Lonza Facilities. In support of
achieving such goals, each Party agrees that, if any aspect of the specific
forecasting and ordering provisions as set forth above in this Article 3 is
determined, based on experience in operating under such provisions, to impact
negatively a Party in its efforts to achieve the above goal, then at such
Party's request the Parties shall meet and discuss in good faith appropriate
modifications to such aspect of the provisions and shall seek to agree on an
amendment to such provisions that better provides for the more efficient
ordering and supply of Bulk Product Components to Altus by Lonza.

                                                              Execution Original

    PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH
            THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S
         APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2
                     OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       24.
<PAGE>

                                    ARTICLE 4

                    QUALITY CONTROL; ACCEPTANCE AND REJECTION

      4.1 QUALITY CONTROL. Lonza shall maintain and follow a quality control and
quality assurance testing program consistent with the Bulk Specifications, cGMP,
and all other requirements of Applicable Law and consistent with industry
standards (the "QUALITY CONTROL PROCEDURES"), which shall include performing the
applicable Acceptance Tests on each Batch of Bulk Product Component. Lonza shall
ensure that all Bulk Product Component supplied to Altus hereunder shall be
manufactured in accordance with the applicable Manufacturing SOPs and cGMP, all
other Applicable Laws, and all other applicable requirements of Regulatory
Authorities, (collectively, "REGULATORY STANDARDS") and shall comply with the
applicable Bulk Specifications. Lonza shall promptly notify Altus in accordance
with the quality agreement of any deviation from Manufacturing SOPs or the
Regulatory Standards that occurs during any Batch process or manufacturing or
any Batch failure, including the details and causes thereof.

      4.2 CERTIFICATES. Lonza shall provide to Altus, accompanying each Batch of
Bulk Product Component delivered to Altus: (a) the Batch number and Purchase
Order number of the delivered Bulk Product Component and (b) a completed and
accurate Certificate of Analysis as to such Batch. Altus or its Affiliate or
designee may test each amount of Bulk Product Component delivered to confirm
that it meets the applicable Bulk Specifications and otherwise complies with the
terms of this Agreement.

      4.3 QUALITY AUDITS. Lonza shall maintain all quality control documentation
and Acceptance Test results for each Batch of Bulk Product Component for a
period and in a manner consistent with Regulatory Standards and the Quality
Agreement. During the Term, Altus may periodically review, upon reasonable prior
notice, such documentation and results, and shall have the right to audit,
survey, verify the adherence of Lonza to the Quality Control Procedures and
Regulatory Standards. In addition to the above and to the Altus representatives
provided for in Section 5.8, in accordance with the quality agreement and upon
reasonable prior written notice to Lonza, Altus shall have the right to have its
representatives visit each Lonza Facility to discuss quality issues and any
related issues with Lonza's manufacturing and management personnel as relating
to manufacture of Bulk Product.

      4.4 ACCEPTANCE AND REJECTION.

            (a) Altus may reject any amount of Bulk Product Component delivered
under this Agreement that does not comply with the warranties set forth in
Section 8.2 (a "DEFECTIVE PRODUCT") by giving written notice of such Defective
Product to Lonza within [***] after receipt thereof. If, as to a particular
delivery of Bulk Product Component, Altus does not so notify Lonza that such
delivery is Defective Product within such [***], Altus will be deemed to have
accepted such quantities of

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      25.

<PAGE>

Bulk Product Component and the Bulk Product Component shall be treated as
meeting the Specifications, but subject to Section 4.4(b). Nothing in this
Section 4.4(a) shall be construed in any way to limit Lonza's warranty under
Section 7.2 or Altus's indemnification rights under Section 8.1.

            (b) If, after Altus's initial acceptance or deemed acceptance of a
delivery of Bulk Product Component ordered by Altus, Altus determines that any
such quantity of Bulk Product Component delivered hereunder is Defective
Product, Lonza shall cooperate fully with any subsequent investigation Altus may
conduct and shall engage in good faith discussions with Altus to determine the
cause of the defect. If the Parties determine (or it is determined by dispute
resolution) that the defect: (i) is due to the Bulk Product Component not having
been manufactured in compliance with applicable Manufacturing SOPs, cGMP and
other Regulatory Standards, being adulterated or misbranded within the meaning
of the FD&C Act, or not complying with the applicable Bulk Specifications at the
time of delivery (where such non-compliance could not reasonably have been
determined by conducting the Acceptance Tests), and (ii) resulted from the
negligence or intentional misconduct of Lonza or its agent, and provided that
such defect was not caused by matters out of Lonza's control (e.g., by Altus
delivering defective raw material to Lonza, or the defect occurring in shipping
by the carrier or post delivery), then Altus may revoke its acceptance with
respect to such quantity of Defective Product by providing written notice to
Lonza of such revocation, provided that such revocation of acceptance occurs
prior to the date [***] delivery by Lonza of the applicable Bulk Product
Component.

            (c) Altus shall return any Defective Product to Lonza [***] or, at
Lonza's request or if return is not practicable, shall destroy any Defective
Product at [***] and certify to Lonza that such destruction is complete, but
subject to Lonza's right to [***] Defective Product to the extent permitted by
the Quality Agreement. With respect to any Defective Product that have been
properly rejected pursuant to Section 4.4(a) or 4.4(b), Altus shall not be
required to pay for such Defective Product under the payment terms of Article 6,
and if Altus already paid Lonza the Transfer Price for the delivery of such
Defective Product, then Lonza shall refund to Altus the total amount of such
payment within [***] of the determination that such delivered material is
Defective Product. At Altus's sole election, Lonza shall replace such Defective
Product as quickly as possible and [***] to deliver such replacement Batches of
Bulk Product Component no later than the delivery timeframes provided in Section
3.3. Altus shall pay Lonza for such replacement Bulk Product Component in
accordance with Article 6, or in the event that Altus has already paid for any
such Defective Product (which payment has not been previously refunded), Lonza
shall replace such Defective Product with conforming Bulk Product Component at
its own expense. For clarity, in the event Altus elects not to receive
replacement Bulk Product Component, and Altus has already paid for the Defective
Product, Lonza shall reimburse Altus an amount equal to the payment made by
Altus for such Defective Product.

            (d) If Lonza disagrees with Altus's determination that certain
quantities of Bulk Product Component delivered by Lonza are Defective Product,
the

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      26.

<PAGE>

Parties will first use good faith efforts to resolve such dispute [***] of
Altus's notice provided under Section 3.5(a) or Section 3.5(b). If the Parties
are unable to resolve such dispute within [***], a sample of such Bulk Product
Component shall be submitted to a mutually acceptable Third Party testing
service. Such Third Party testing service shall determine whether the Bulk
Product Component meets the applicable Bulk Specifications and/or otherwise is
defective, and the Parties agree that such testing service's determination shall
be final and determinative. The Party against whom the Third Party laboratory
rules shall bear all costs of the Third Party testing.

                                    ARTICLE 5

                             REGULATORY OBLIGATIONS

      5.1 FACILITIES LICENSES. Lonza shall obtain and maintain for each Lonza
Facility, at its sole cost, all permits, licenses and approvals (including
facilities licenses) needed for Lonza to be able to manufacture and supply all
Bulk Product Components in compliance with cGMP and Applicable Law ("Facilities
Licenses"), in a timely manner such that Lonza is able to meet is manufacturing
and supply obligations under this Agreement. Lonza would keep Altus regularly
informed about status of all such Facilities Licenses and shall provide Altus
copies thereof upon request. Lonza shall ensure that each Lonza Facility
complies with cGMP and all other Applicable Law with regards to its
manufacturing and supply of Bulk Product Components. Lonza shall use best
efforts to resolve as soon as possible any issues that arise in its seeking or
maintaining Facilities Licenses, including completely addressing and rectifying
any deviations or other issues raised in any Warning Letter from the FDA or any
similar warning or objection by a Regulatory Authority.

      5.2 INFORMATION FOR REGULATORY APPLICATIONS. Upon Altus's written request,
Lonza shall provide to Altus the complete Master Batch Records and specific
Manufacturing and Analytical SOP's and updates as defined in the Quality
Agreement, and copies of the relevant documents containing any other Lonza
Technology used in manufacturing each Bulk Product Component. Altus has the
right to review and copy the executed, completed Batch Records for each Batch,
all as needed for Altus to prepare the CMC Sections for any particular
Regulatory Application that Altus (or its Affiliate or licensee) intends to file
or for any other appropriate regulatory purpose relating to a Bulk Product
Component or the Final Product. All such Information shall be provided in
English. Lonza shall prepare and maintain the Batch Records for each Batch of
Bulk Product Component manufactured hereunder, and shall provide Altus access to
such Batch Records for review and inspection, and shall provide copies thereof
to Altus, at Altus' expense for actual out-of-pocket copying costs and the costs
(at an agreed FTE rate) for Lonza's internal employee time required for such
copying, if so requested by Altus.

      5.3 REGULATORY APPLICATIONS FOR FINAL PRODUCT. Altus (or its Affiliate or
licensee) shall have the exclusive right to prepare and submit any and all
Regulatory Applications regarding Final Products and/or Bulk Product Component
(including INDs and NDAs), and including filing any amendments or supplements
thereto and pursuing

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      27.

<PAGE>

such applications and filings to approval or registration. Any and all such
Regulatory Applications regarding Final Product and/or Bulk Product Component
will be owned solely by and held in the name of Altus (or its Affiliate or
licensee, as applicable). To the extent required or appropriate under Applicable
Law, any such Regulatory Applications regarding Final Product and/or Bulk
Product Component shall list Lonza as the manufacturer of the applicable Bulk
Product Components under this Agreement. Lonza shall have no rights in or to any
such Regulatory Application.

      5.4 REGULATORY ASSISTANCE. Without limiting Section 5.2, with respect to
any application or filings reasonably needed by Altus (or its Affiliate or
licensee) to obtain or maintain Regulatory Approvals for any Final Product, and
any record-keeping, audits, inspections and audits required by Regulatory
Authorities relating to the manufacture and/or supply of all Bulk Product
Components by Lonza hereunder, Lonza shall reasonably cooperate with and assist
Altus in all such matters, including providing any additional Information needed
for such applications, filings or activities and any additional support relating
to Bulk Product Component as reasonably requested by Altus, and Altus shall
reimburse Lonza for any actual out-of-pocket costs of providing such Information
and assistance, in amounts to be agreed prior to the services.

      5.5 CHANGES IN MANUFACTURING PROCESS. Lonza shall not change or modify any
of the Manufacturing SOPs, or otherwise make any change in the materials,
equipment, process or procedures used to manufacture or test any Bulk Product
Component that would require a filing with a Regulatory Authority and/or that
would reasonably be expected to or affects Lonza's ability to manufacture the
Bulk Product Components in accordance with the Bulk Specifications or the terms
of this Agreement, without first obtaining Altus' prior written approval. No
changes to Manufacturing SOPs or the Master Batch Records shall be made except
in accordance with the change control procedure of the Quality Agreement. Lonza
shall disclose all proposed changes in such manufacturing and testing materials,
equipment, process or procedure to Altus at a level that would be sufficient to
allow Altus to understand such changes and comply with Regulatory Standards. If
Altus agrees to allow any such change requiring Altus's approval to be
implemented, then the Parties shall revise Manufacturing SOPs and the relevant
Bulk Specifications in writing accordingly, if applicable, in compliance with
the requirements of the Quality Agreement. Any actual costs incurred by Lonza in
making changes to the Manufacturing SOPs that are requested by Altus shall be
reimbursed by Altus, in amounts to be agreed by the Parties in writing prior to
performing such changes.

      5.6 COMPLIANCE WITH LAWS. In performing its obligations hereunder, Lonza
shall comply with the Regulatory Standards and all Applicable Laws. Lonza shall
obtain and maintain all government permits, including without limitation health,
safety and environmental permits, necessary for the conduct of the actions and
procedures undertaken to manufacture and supply Bulk Product Component during
the Term.

      5.7 RECORDS. Lonza shall keep complete, accurate and authentic accounts,
notes, data and records pertaining to the manufacture, processing, testing,
storage, and distribution of the Product, including without limitation master
production and control records, in accordance with Regulatory Standards. Lonza
shall retain such records for a

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      28.

<PAGE>

period and in a manner consistent with Regulatory Standards and shall make
available to Altus copies of such records and shall permit Altus to inspect the
originals of such records as maintained by Lonza, on reasonable notice. After
such time period, Lonza shall notify Altus prior to the destruction of any
records retained under this Section 5.7 and, at Altus's request, shall transfer
such records to Altus.

      5.8 INSPECTIONS BY ALTUS. Lonza shall permit Altus to inspect, as
reasonably needed, that portion of the Lonza Facility where Bulk Product
Component is manufactured or stored and review such Bulk Product Component
documents as is reasonably necessary for the purpose of assessing Lonza's
compliance with the Manufacturing SOPs, cGMP, the Bulk Specifications, the
Regulatory Standards, and applicable chemical manufacturing controls. Such
inspection and document review shall be conducted upon reasonable prior written
notice by Altus prior to the proposed inspection (except in the event of a
reasonable, urgent concern by Altus regarding the quality of Bulk Product
Component, in which case Altus may conduct the inspection as soon as
practicable), at a time and date mutually agreeable to the Parties and in
accordance with the quality agreement. In addition, Altus shall have the right
to have an employee or agent present at the Lonza Facility during the
preparation for or conduct of any manufacturing or production run for
manufacture or packaging of a Batch of Bulk Product Component, and such employee
or agent shall be free to inspect and oversee all aspects of such preparation or
production run and to comment to Lonza thereupon. Lonza shall provide such Altus
employee or agent a suitable office equipped with a phone line and high-speed
internet connection and other standard office equipment and supplies as needed,
for use by such employee or agent in conducting the inspection and oversight
activities during such production run.

      5.9 REGULATORY INSPECTIONS.

            (a) INSPECTION BY REGULATORY AUTHORITIES. Upon the request of any
Regulatory Authority having jurisdiction over the manufacture of Bulk Product
Component hereunder, such Regulatory Authority shall have access to observe and
inspect Lonza's facilities and procedures used for the manufacture, release and
stability testing, and/or warehousing of all Bulk Product Components and to
audit such facilities for compliance with cGMP and/or other applicable
regulatory standards. Lonza specifically agrees to cooperate with any inspection
by a Regulatory Authority, whether prior to or after Regulatory Approval of a
Final Product, and to provide Altus a copy of any inspection or audit report
resulting form any such inspection. If Lonza is purchasing [***] from a Third
Party manufacturer for use in manufacturing Bulk Product Component, Lonza [***]
to ensure that such manufacturer's facilities and procedures are similarly
subject to the provisions of this Section 5.9(a) as to the manufacture of such
[***], and to ensure that Altus is provided copies of any inspection or audit
report of such Third Party relating to such [***].

            (b) NOTIFICATION OF INSPECTIONS. Lonza agrees to notify Altus within
[***] any written or oral inquiries, notifications or inspection activity by any
Regulatory Authority in regard to Bulk Product Component to be supplied to Altus
hereunder. Lonza shall provide a reasonable description of any such governmental
inquiries,

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      29.

<PAGE>

notifications or inspections promptly, but in no event later than [***] such
notification, inquiry or inspection. Lonza shall furnish to Altus (i) [***]
after receipt, any report or correspondence issued by any Regulatory Authority
in connection with such notification, inquiry or inspection, including any FDA
Form 483 (List of Inspectional Observations) or applicable portions of any FDA
Warning Letters which pertain to the Bulk Product Component (or any equivalent
in another country or jurisdiction), and (ii) [***] prior to the time it
provides to any Regulatory Authority, copies of proposed responses or
explanations relating to items set forth above (each, a "Proposed Response"), in
each case redacted of trade secrets or other confidential or proprietary
information of Lonza that are unrelated to the obligations under this Agreement
or are unrelated to Bulk Product Component or its manufacture. Lonza shall
discuss with Altus and consider in good faith any comments provided by Altus on
the Proposed Response. After the filing of a response with the FDA or other
Regulatory Authority, Lonza shall notify Altus of any further contacts with such
Regulatory Authority relating to the subject matter of the response.

            (c) REMEDIAL ACTIONS. Lonza shall notify Altus immediately in
writing in the event any action is taken or threatened by a Regulatory Authority
relating to the manufacture or storage of Bulk Product Component by Lonza, or
relating to the Lonza Facility in which such manufacture or storage occurs, or
which may impair the ability of Lonza to manufacture Bulk Product Component
(including without limitation any impairment to Lonza's ability to manufacture
Bulk Product Component conforming to the applicable Bulk Specifications) in
accordance with this Agreement. In any event, Lonza shall [***] to [***] and
[***] any issues, concerns or warnings from any Regulatory Authority that might
affect Lonza's ability to manufacture and supply Bulk Product Component in
accordance with this Agreement. To the extent Lonza must implement a plan of
remediation or for other modifications or changes to its Lonza Facility or its
manufacturing processes in order to address and resolve any such issues,
concerns or warnings from any Regulatory Authority, Lonza shall prepare such
plan as soon as possible, shall provide a draft of the plan to Altus for review
and comment, and shall implement all reasonable comments of Altus as soon as
possible, and shall implement and complete all aspects of the agreed plan [***].

            (d) DAMAGES FOR REGULATORY FAILURES. If Lonza fails to deliver on a
timely basis Bulk Product Component ordered by Altus under this Agreement due to
either: (i) failure of Lonza to obtain or maintain all needed Facilities
Licenses; or (ii) a determination by the FDA that the Bulk Product Component is
"misbranded or adulterated" within the meaning of the FD&C Act due to any
manufacturing problem or issue at the Lonza Facility, or any other similar
disability raised or imposed by a Regulatory Authority, then Lonza shall
indemnify and hold Altus harmless from any and all losses resulting from lost
sales caused directly by such failure to deliver, but not in an amount exceeding
the [***]. Further, if such failure to deliver permits Altus under the terms of
this Agreement, under Section 3.10 or any other provision of this Agreement, to
engage a Third Party manufacturer to supply the applicable Bulk Product
Component due to such failure by Lonza, then Lonza shall also pay to Altus [***]
and of [***] for [***] that are not incorporated into Bulk Product Component.

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      30.

<PAGE>

      5.10 RECALLS.

            (a) RESPONSIBILITY. In the event that a Recall (as defined below) of
any Final Product distributed by Altus or its Affiliate or licensee is required
or recommended by a Regulatory Authority or other governmental agency or
authority of competent jurisdiction, or if a Recall is reasonably deemed
advisable by Altus, such Recall shall be promptly implemented and administered
by Altus in a manner which is appropriate and reasonable under the circumstances
and in conformity with accepted trade practices and with all Applicable Law of
the relevant jurisdiction(s). The costs of any such Recall shall be borne by the
Party or Parties whose actions or omissions caused the Recall to be necessary or
deemed advisable, and subject also to Section 4.4. In particular, Lonza shall
pay all such costs of any such Recall caused by Lonza manufacturing defects in
any Bulk Product Component supplied by Lonza (for example, due to Lonza's
failure to manufacture a Bulk Product Component included in such Final Product
in accordance with the applicable Bulk Specifications or cGMP requirements),
including costs incurred by Altus for [***] and other [***] related to such
[***] (such as [***] as set forth in [***])). Notwithstanding the foregoing,
Lonza shall have no obligation to pay costs of a Recall of any Final Product to
the extent such Recall is: (a) due to defects in the Final Product other than
manufacturing defects in the Bulk Product Components as supplied by Lonza, (b)
caused by actions of Altus or Third Party occurring after the Bulk Product
Component is delivered by Lonza to Altus's carrier, (c) due to packaging or
labeling defects for which Altus or any Third Party has responsibility or (d)
due to and caused by any other breach by Altus of its duties under this
Agreement. For the avoidance of doubt and subject to the general limitations of
liability under this Agreement, Lonza shall be solely responsible for the costs
and expenses of a Recall that is directly caused by a Lonza manufacturing defect
in Bulk Product Component supplied to Altus. To the extent that any Recall is
due to a cause out of Lonza's control, Lonza shall not be responsible for the
costs of the Recall attributable to such other cause.

            (b) COMMUNICATION. Each Party shall keep the other fully and
promptly informed of any notification, event or other information, whether
received directly or indirectly, which might affect the marketability, safety or
effectiveness of Final Products sold or distributed by Altus or its Affiliate or
licensee or might result in a Recall or Seizure of Final Products by the FDA or
other Regulatory Authority.

            (c) REPLACEMENT; REFUND. In the event of any Recall or Seizure of
Final Product arising out of or resulting from Lonza's supplying defective Bulk
Product Component or other breach of this Agreement by Lonza, Lonza shall, at
the election of Altus, and in addition to the obligations of Lonza under Article
3 and the other terms of the Agreement, either:

                  (i) supply replacement Bulk Product Components that meet the
applicable Bulk Specifications, without charge to Altus, in an amount sufficient
to replace the amount of each of the Bulk Product Components needed to
manufacture the Final Product that is Recalled or Seized (including that amount
of Bulk Product Components incorporated into Final Products Recalled or Seized),
or

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      31.

<PAGE>

                  (ii) refund to Altus, or give credit to Altus against
outstanding receivables due from Altus against the price of Bulk Product
Component to be delivered to Altus in the future, in amounts equal to the price
paid by Altus to Lonza for the Bulk Product Components needed to manufacture the
Final Product so Recalled or Seized (including that Bulk Product Components
incorporated in Final Product so Recalled or Seized) plus the reasonable
transportation costs incurred by Altus and not recovered by Altus in respect of
such Recalled or Seized Final Product.

            (d) REIMBURSEMENT.

                  (i) BY LONZA. In the event of any Recall or Seizure of Final
Product arising out of or resulting from a [***] of this Agreement, Lonza shall
pay Altus's [***] and [***] incurred in connection with administering such
Recall or Seizure of the Final Product.

                  (ii) BY ALTUS. In the event of any Recall or Seizure of Final
Product arising out of or resulting from Altus's [***], Altus shall pay Lonza's
[***] and [***] (if any) incurred in connection with its providing assistance to
Altus in administering such Recall or Seizure of the Final Product.

            (e) DEFINITIONS.

                  (i) RECALL. For purposes of this Section 5.10, "Recall" shall
mean any action by Altus and/or its Affiliates or sublicensees to recover title
or possession or halt distribution, prescription or consumption of Final
Products sold or shipped to Third Parties by Altus or its Affiliate or licensee.
The term "Recall" also applies to Final Product which would have been subject to
recall or withdrawal if it had been sold or shipped.

                  (ii) SEIZURE. For purposes of this Section 5.10, "Seizure"
shall mean any action by the FDA or other Regulatory Authority or governmental
agency or authority of competent jurisdiction to detain or destroy Final
Products or prevent the distribution, prescription, consumption or release of
such Final Products.

      5.11 ADVERSE EVENT REPORTING. It is understood and agreed that Altus (or
its Affiliate or licensee) shall have the sole right and responsibility for
reporting any adverse events to the applicable and appropriate Regulatory
Authorities. Lonza shall provide Altus all reasonable assistance in complying
with such reporting requirements. Lonza shall notify Altus, in accordance with
the requirements of the Quality Agreement, of any information of which Lonza
becomes aware concerning any side effect, injury, toxicity or sensitivity
reaction, or any unexpected incident, and the severity thereof, that is
associated with the manufacturing of Bulk Product Component.

      5.12 QUALITY AGREEMENT. The responsibilities of the quality units of each
Party related to the manufacture of all Bulk Product Component shall be
described in a

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      32.

<PAGE>

quality agreement between the Parties, substantially in accordance with
industry standards (the "Quality Agreement"). The Parties agree to negotiate and
execute the Quality Agreement within [***] following the Effective Date (or such
other period of time as may be mutually agreed by the Parties). Such
responsibilities shall include, without limitation, (i) the specific content of
the Certificate of Analysis, (ii) the nature of the Batch Record review process,
including notification of deviations associated with the Manufacturing SOPs, and
(iii) a table of key contacts associated with the manufacturing, regulatory,
quality control and quality assurance functions. Further, if Lonza is at any
time not in compliance with its obligations under the Quality Agreement, Lonza
shall cooperate in good faith with Altus to cure such non-compliance as soon as
possible, and Lonza shall reimburse Altus for all its actual costs and expenses
in working with Lonza to cure such non-compliance.

                                    ARTICLE 6

                                 FINANCIAL TERMS

      6.1 BULK PRODUCT COMPONENT TRANSFER PRICES. The Transfer Price for a
particular Batch of Bulk Product Component that is manufactured by Lonza during
a particular calendar year and delivered to Altus under this Agreement shall be
as set forth in the applicable column in the transfer price schedule on EXHIBIT
I, which Transfer Price shall be subject to adjustment (if any) in accordance to
Section 6.2. As the Transfer Prices include charges for "change over" days,
Lonza covenants that in all cases it shall [***] to minimize such number of days
required to complete the [***] in any manufacturing campaign under this
Agreement.

      6.2 ADJUSTMENTS TO TRANSFER PRICES; MINIMUM PAYMENT.

            (a) The Transfer Price for each Batch of Bulk Product Component as
set forth in Exhibit I is based on an exchange rate of [***] per [***]; since
the Bulk Product Components are to be manufactured in [***] and the Transfer
Pricing is thus based on costs in [***], if the above exchange rate is higher at
the applicable payment time (i.e., more [***]), then the Transfer Price will be
adjusted downward an equivalent amount for such payment by Lonza, and vice
versa. Further, commencing on [***], and on [***] of each calendar year
thereafter during the Term, the Transfer Price for each Batch of Bulk Product
Component as set forth in Exhibit I shall be adjusted by the [***] in the [***]
since the prior [***] (as published by the [***]). Such adjustments shall be
agreed on by the Parties and shall be effective for the next following calendar
year, and shall be set forth in a written amendment to the prices in Exhibit I
hereto for such calendar year.

            (b) Promptly after completion by Lonza of at least [***] commercial
Batches of a particular Bulk Product Component (following [***] Batches), the
Parties shall discuss reasonably and in good faith and agree on: (a) the
estimated typical yield (in kilograms of conforming Product Component) per Batch
of such Bulk Product Component being manufactured (the "Expected Yield" for each
Batch of the Bulk Product Component), the Parties will at Altus' request meet
and discuss in good faith

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      33.

<PAGE>

converting the ordering and transfer pricing for such Bulk Product Component to
kilograms per Batch, and if agreement is reached, will reflect such change in a
written amendment to this Agreement, which amendment would also modify the
applicable other Sections of the Agreement that involve Batches (with
appropriate changes to kilograms of Bulk Product Component). The Parties agree
that such kg price shall be [***] and provide [***] for Lonza, and would include
a [***] resulting from ongoing yield improvements.

            (c) Notwithstanding the foregoing, the Transfer Price payable by
Altus for: (i) all Batches of Lipase ordered after the orders submitted under
Section 3.3(a) for year [***] shall be the Transfer Price applicable to Batches
of Lipase to be manufactured in [***], as specified in Exhibit I (regardless of
the year such Batches are manufactured), until such time as Altus has ordered a
total of [***] Batches of Lipase, and thereafter the Transfer Price for Lipase
Batches shall be the Transfer Price applicable, under Exhibit I, for the year in
which the Batch was manufactured; (ii) all Batches of Amylase ordered after the
orders submitted under Section 3.3(a) for year [***] shall be the Transfer Price
applicable to Batches of Amylase to be manufactured in [***], as specified in
Exhibit I (regardless of the year such Batches are manufactured), until such
time as Altus has ordered a total of [***] Batches of Amylase, and thereafter
the Transfer Price for all Amylase Batches shall be the Transfer Price
applicable, under Exhibit I, for the year in which the Batch was manufactured;
and (iii) all Batches of Protease ordered after the orders submitted under
Section 3.3(a) for year [***] shall be the Transfer Price applicable to Batches
of Protease to be manufactured in [***], as specified in Exhibit I (regardless
of the year such Batches are manufactured), until such time as Altus has ordered
a total of [***] Batches of Protease , and thereafter the Transfer Price for
Protease Batches shall be the Transfer Price applicable, under Exhibit I, for
the year in which the Batch was manufactured. An interest fee of [***] per annum
would also be payable to Lonza in [***] if Altus does not meet in [***] (by
placing binding Purchase Orders for manufacturing in [***]) for Batch purchases
totaling CHF [***], which fee is to be calculated based on the number of days
after the end of 2008 that the difference between CHF [***] and the amount,
equal to the difference between CHF [***] and the actual Transfer Prices paid
for Batches manufactured in [***] and then in [***], remains outstanding.

      6.3 INVOICE AND PAYMENT. Lonza shall provide to Altus a written invoice,
based on the then-applicable Transfer Price, for each Batch of Bulk Product
Component for which manufacturing and quality control testing has been completed
and Lonza has delivered to Altus the completed Certificate of Analysis for the
Bulk Product Component. Such invoice shall be based on the Transfer Price then
applicable to the Bulk Product Component (as adjusted pursuant to Section 6.2).
All payments due hereunder to Lonza shall be paid in Swiss Francs not later than
[***] from the date of invoice, subject to Section 4.4(c).

      6.4 MANUFACTURING SUPPORT PAYMENTS.

            (a) PROCESS LIMITS EVALUATION. Lonza acknowledges that Altus has
completed payment to Lonza of all amounts owed for Lonza to conduct and complete
the process limits evaluations as required in Section 2.5.

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      34.

<PAGE>

            (b) VALIDATION CAMPAIGN SUPPORT. As funding for the manufacturing
validation work conducted by Lonza pursuant to Section 2.4, upon completion of
such work and delivery to Altus of the required report, Altus shall pay Lonza
[***] CHF based on a Lonza invoice in such amount.

            (c) STABILITY STUDIES. Upon completion by Lonza of the stability
studies and deliver of the required interim or final report pursuant to Section
2.6, Altus shall pay Lonza a total of [***] CHF for the three Bulk Product
Components per annum based on a Lonza invoice in such amount.

      6.5 TAXES AND SIMILAR CHARGES. The Parties shall cooperate and use
commercially reasonable efforts to minimize the imposition of sales, excise, and
other taxes and government charges on the sale and delivery of Bulk Product
Component purchased by Altus. Altus shall be responsible for payment of any
applicable sales taxes imposed, and Lonza shall be responsible for any other
assessments and fees of any nature levied or incurred on account of any payments
from Altus to Lonza accruing under this Agreement, by national, state or local
governments, or value added or similar taxes. Any income or other taxes which
Altus is required by Applicable Law to pay or withhold on behalf of Lonza with
respect to payments and any other monies payable to Lonza under this Agreement
shall be deducted from the amount of such payments and other monies due and paid
to the relevant competent taxing authority. Altus shall furnish Lonza with proof
of such payments. Any such tax required to be paid or withheld shall be an
expense of and borne solely by Lonza. Altus shall promptly provide Lonza with a
certificate or other documentary evidence and provide reasonable assistance to
enable Lonza to support a claim for a refund or a foreign tax credit with
respect to any such tax so withheld or deducted by Altus. Altus and Lonza will
reasonably cooperate in completing and filing documents required under the
provisions of any applicable tax treaty or under any other applicable law, in
order to enable Altus to make such payments to Lonza without any deduction or
withholding, if possible.

                                    ARTICLE 7

                          INTELLECTUAL PROPERTY MATTERS

      7.1 LICENSE TO LONZA. Subject to the terms of this Agreement, Altus hereby
grants to Lonza during the Term a non-exclusive, non-transferable, royalty-free
license (without the right to sublicense) under the Altus Manufacturing
Technology, the Altus IP and any Materials transferred to Lonza by Altus solely
as needed to manufacture and supply the Bulk Product Components ordered by Altus
under this Agreement.

      7.2 LICENSE TO ALTUS. Subject to the terms of this Agreement, Lonza hereby
grants Altus a non-exclusive, irrevocable, royalty-free license (with the full
rights to sublicense to Altus' contract manufacturers or to its licensees of
Final Product) under the

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                              35.

<PAGE>

Lonza Technology solely as needed to manufacture or have manufactured Bulk
Product Components for use in making Final Product for clinical development and
commercial sale worldwide.

      7.3 MANUFACTURING INVENTIONS. Lonza shall disclose to Altus any and all
Manufacturing Inventions made by or on behalf of Lonza or its Affiliate. Altus
shall own the entire right, title and interest in and to all Manufacturing
Inventions, and Lonza shall, and hereby does (and shall cause its Affiliates to)
assign to Altus the entire right, title and interest in and to any Manufacturing
Inventions made by or on behalf of Lonza or its Affiliate. Lonza shall execute
and deliver (and shall cause its Affiliates to execute and deliver, if
applicable) to Altus such instruments and documents as may be needed to obtain
and/or perfect such assignment or any patent rights claiming any such
Manufacturing Inventions, and Lonza shall reasonably assist Altus at Altus'
expense in seeking any such patent rights.

      7.4 LIMITED GRANT-BACK LICENSE. Subject to the terms of this Agreement,
Altus hereby grants to Lonza a non-exclusive, perpetual, worldwide, royalty-free
license (without the right to sublicense) under any of the Manufacturing
Inventions assigned to Altus by Lonza under Section 7.3 that derives from or is
an improvement to the Lonza Technology solely for the purpose of Lonza (or its
Affiliate) manufacturing products as a custom manufacturer for Third Parties.
Notwithstanding the foregoing, Lonza shall have no right, and no license is
granted hereunder, to use such Manufacturing Inventions in connection with any
product that competes with a Bulk Product Component or the Final Product.

      7.5 NO OTHER RIGHTS. Nothing in this Agreement shall be deemed or
interpreted to convey to Lonza any ownership, license or other rights in or to
any of the Altus Manufacturing Technology, the Altus IP, the Materials or any
other Altus intellectual property or proprietary information, all of which shall
be owned exclusively by Altus, subject only to the applicable limited license
rights as expressly granted in Section 7.1 or 7.4. Lonza shall have no rights to
develop, promote, market, produce, distribute, sell, or otherwise use any Bulk
Product Component except as needed to satisfy the manufacturing and supply
obligations to Altus as specifically set forth in this Agreement. Lonza hereby
covenants that Lonza and its Affiliates shall not use or practice, itself or
with or on behalf of any Third Party, any Altus Manufacturing Technology, Altus
IP, Materials or other Altus intellectual property or proprietary information
for any use or purpose other than for the limited purposes expressly permitted
in Section 7.1 and/or 7.4. Altus is and shall own the entire right, title and
interest in and to all Master Batch Records, Batch Records, Materials (including
cell lines, media composition, etc.), Bulk Specifications, Manufacturing SOPs,
Certificates of Analysis, development reports, [***] specifications, analytical
SOPs, and any other documents created by either Party relating directly to the
manufacture of Bulk Product Component, and Lonza shall assign to Altus any
interest it may have in any of the foregoing.

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      36.

<PAGE>

                                    ARTICLE 8

                         REPRESENTATIONS AND WARRANTIES

      8.1 REPRESENTATIONS AND WARRANTIES. Each Party hereby represents and
warrants as follows:

            (a) EXISTENCE AND POWER. It is duly organized, validly existing and
in good standing under the laws of the state or country in which it is
organized.

            (b) DUE AUTHORIZATION AND ENFORCEMENT OF OBLIGATIONS. It has the
power and authority and the legal right to enter into this Agreement to perform
its obligations hereunder, and has taken all necessary action on its part to
authorize the performance of such obligations. This Agreement has been duly
executed and delivered on behalf of such party, and constitutes a legal, valid,
binding obligation, enforceable against such party in accordance with its terms.

            (c) NO CONFLICT. The execution and delivery of this Agreement and
the performance of such Party's obligations hereunder (i) do not conflict with
or violate any requirement of applicable laws or regulations and (ii) do not
conflict with, or constitute a default or require any consent under, any
contractual obligation of such party.

      8.2 WARRANTIES OF LONZA.

            (a) Lonza warrants and covenants that all Bulk Product Component
delivered hereunder shall (i) conform to the applicable Bulk Specifications with
the exception of the engineering lots; (ii) be free and clear of any and all
encumbrances, liens, or other Third Party claims (but provided that the
foregoing warranty in this subclause (ii) does not, and shall not be deemed to,
cover any claims by a Third Party that the Bulk Product Component, or its
manufacture, infringes or violates such Third Party's intellectual property
rights); (iii) be manufactured in compliance with applicable Manufacturing SOPs,
cGMP and other Regulatory Standards; (iv) not be adulterated or misbranded
within the meaning of the FD&C Act; and (v) not be articles that, under the
provisions of the FD&C Act, may not be introduced into interstate commerce.

            (b) Lonza warrants and covenants to Altus that Lonza will not, in
the course of performing the manufacturing obligations hereunder, infringe or
misappropriate any intellectual property of any other person or entity.

            (c) Lonza warrants and covenants that it shall not use any employee
or consultant that has been debarred by a Regulatory Authority, or, to the best
of its knowledge, is the subject of debarment proceedings by a Regulatory
Authority.

            (d) Lonza warrants and covenants that it shall not enter into any
agreement or arrangement with any other entity that would prevent or in any way
interfere with Lonza's ability to perform it obligations hereunder.

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      37.

<PAGE>

      8.3 WARRANTIES OF ALTUS.

            (a) Altus represents and warrants that, to its present knowledge as
of the Effective Date, the manufacture of Bulk Product Component in accordance
with the Altus Manufacturing Technology, and the sale of Bulk Product Component
to Altus as contemplated herein, does not infringe any patent rights of a Third
Party.

            (b) Altus represents and warrants that it will use commercially
reasonable, diligent efforts to secure the supply of the applicable cell lines
and the respective technical data that are to be provided by [***].

                                    ARTICLE 9

                                 INDEMNIFICATION

      9.1 LONZA INDEMNITY. Lonza agrees to indemnify, hold harmless, and defend
Altus and its Affiliates and licensees, and their respective directors,
officers, employees, and agents (the "ALTUS INDEMNITEES") from and against any
and all claims, costs, expenses, liabilities, damages, losses and harm
(including reasonable legal expenses and attorneys' fees regardless of outcome)
arising out of or resulting from any Third Party suits, claims, actions,
allegations or demands against any Altus Indemnitee (collectively, "CLAIMS")
resulting from or caused by: (a) Lonza's manufacture or supply of Bulk Product
Component (other than Claims that fall within the scope of Section 8.2(a)
below); (b) the negligence, recklessness or willful misconduct of Lonza or its
officers, directors, employees, or agents; or (c) Lonza's material breach of its
obligations, warranties, representations or covenants under this Agreement,
except in each case to the extent directly caused by the negligence,
recklessness or willful misconduct of Altus or its officers, directors,
employees, or agents.

      9.2 ALTUS INDEMNITY. Altus agrees to indemnify, hold harmless, and defend
Lonza and its Affiliates, and their respective directors, officers, employees,
and agents (the "LONZA INDEMNITEES") from and against any and all Third Party
claims, costs, expenses, liabilities, damages, losses and harm (including
reasonable legal expenses and attorneys' fees regardless of outcome) arising out
of or resulting from any Third Party suits, claims, actions, allegations or
demands against a Lonza Indemnitee (collectively, "CLAIMS") resulting from or
caused by: (a) infringement of a Third Party patent claiming Bulk Product
Component, or claiming a method of manufacture of Bulk Product Component which
method is within the Altus Manufacturing Technology; (b) the negligence,
recklessness or willful misconduct of Altus or its officers, directors,
employees, or agents; or (c) Altus's material breach of its obligations,
warranties, representations or covenants under this Agreement, except in each
case to the extent directly caused by the negligence, recklessness or willful
misconduct of Lonza or its officers, directors, employees, or agents.

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      38.

<PAGE>

      9.3 INDEMNIFICATION PROCEDURES. To exercise its right to indemnification
under Section 8.1 or 8.2 (as applicable), a Party (the "Indemnitee") shall give
written notice to the other Party of any Claim that is subject to
indemnification promptly after learning of such Claim, and the other Party (the
"Indemnifying Party") shall assume the defense of such Claim with counsel
reasonably satisfactory to the Indemnitee. If such defense is assumed by the
Indemnifying Party with counsel so selected, the Indemnifying Party will not be
subject to any liability for any settlement of such Claim made by the Indemnitee
(or any other party related to the Indemnitee) without the Indemnifying Party's
consent (but such consent will not be unreasonably withheld or delayed), and
will not be obligated to pay the fees and expenses of any separate counsel
retained by the Indemnitee (or any other party related to the Indemnitee)with
respect to such Claim.

      9.4 INSURANCE. Lonza shall, at its own expense, obtain and maintain
throughout the Term and for a period of time thereafter consistent with its
obligation to indemnify Altus pursuant to Section 8.1, (a) product liability
insurance providing protection in the amount of at least [***] and at least
[***] against any Claims based upon any alleged defect in, or otherwise caused
by, any Bulk Product Component purchased pursuant to this Agreement and (b)
general liability insurance providing protection in the amount of at least [***]
in aggregate against any Claims based upon any act or alleged activity of Lonza
pursuant to this Agreement. Lonza shall furnish to Altus upon request and at
least annually a Certificate of Insurance evidencing compliance with the
provisions of this Section 7.3. The existence of such coverage shall in no way
limit Lonza's liability or obligations hereunder.

                                   ARTICLE 10

                                 CONFIDENTIALITY

      10.1 CONFIDENTIALITY. The Parties acknowledge and agree that all
Information disclosed by one Party (the "DISCLOSING PARTY") to the other Party
(the "RECEIVING PARTY") pursuant to this Agreement or to any other agreement
between the Parties shall be the "Confidential Information" of the Disclosing
Party and shall be subject to the restrictions on disclosure and use set forth
in this Article 10. Except to the extent expressly authorized by this Agreement
or otherwise agreed to in writing by the Parties, each Party agrees that it
shall keep confidential and shall not publish or otherwise disclose to any other
person or party, and shall not use for any purpose other than as expressly
permitted or provided for in this Agreement, any Confidential Information of the
other Party. The foregoing obligation shall not apply, however, to any
Confidential Information of a Disclosing Party that the Receiving Party can
demonstrate, by competent evidence:

            (a) was already known to the Receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the Disclosing
Party;

            (b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party;

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      39.

<PAGE>

            (c) became part of the public domain no act or omission of the
Receiving Party;

            (d) was disclosed to the Receiving Party, other than under an
obligation of confidentiality to a Third Party, by a Third Party who had no
obligation to the Disclosing Party not to disclose such information to others;
or

            (e) was independently developed by employees or agents of the
Receiving Party who were unaware of and did not have access to Confidential
Information of the Disclosing Party.

For clarity, Lonza agrees and acknowledges that the Bulk Specifications are the
Confidential Information of Altus and that, as a result, Lonza owes Altus a duty
of confidentiality under this Article 10 with respect thereto.

      10.2 AUTHORIZED DISCLOSURE. A Receiving Party may disclose Confidential
Information of the Disclosing Party to the extent such disclosure is reasonably
necessary for the following reasons:

            (a) regulatory filings, including filings with the FDA or other
Regulatory Authorities or with the U.S. Securities Exchange Commission or
similar agencies;

            (b) complying with Applicable Law or valid court orders; and

            (c) disclosure to Affiliates and/or to prospective or actual
licensees or investors or to prospective acquirors or merger partners and to
professional advisors of any of the foregoing, each who have a "need to know"
such Confidential Information and who agree in writing to be bound by similar
terms of confidentiality.

Further, notwithstanding the requirements of Section 10.1, a Receiving Party may
disclose specific Confidential Information of the other Party to the extent such
disclosure is required by valid court order or other legal process, provided
that such Receiving Party will, except where impracticable, give reasonable
advance notice to the Disclosing Party of such required disclosure and permit
the Disclosing Party to seek a protective order and/or confidential treatment of
such information. In any event, each Parties agrees to take all reasonable
actions to avoid any unauthorized use or disclosure of the Confidential
Information of the other Party.

      10.3 TERMS OF THIS AGREEMENT. The Parties acknowledge that the terms of
this Agreement shall be treated as Confidential Information of both Parties.
Notwithstanding the foregoing, such terms may be disclosed by a Party: (a) to
individuals or entities covered by Section 10.2(c); (b) to comply with any
applicable governmental regulations and legal requirements; and (c) as necessary
for filings with the U.S. Securities Exchange Commission, provided that the
Party uses reasonable efforts to seek confidential treatment of such information
in connection with such filing. Neither Party will make any announcement or
other public statement concerning the existence or terms of this

                                                              Execution Original

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      40.
<PAGE>

Agreement shall be treated as Confidential Information of both Parties.
Notwithstanding the foregoing, such terms may be disclosed by a Party: (a) to
individuals or entities covered by Section 10.2(c); (b) to comply with any
applicable governmental regulations and legal requirements; and (c) as necessary
for filings with the U.S. Securities Exchange Commission, provided that the
Party uses reasonable efforts to seek confidential treatment of such information
in connection with such filing. Neither Party will make any announcement or
other public statement concerning the existence or terms of this Agreement
except with the consent of the other Party, such consent not to be unreasonably
withheld, or to the extent public disclosure of the existence or terms of the
Agreement is required by Applicable Law. Further, neither Party will make any
announcement or other public statement concerning* matters relating to the
conduct of or occurrences under this Agreement except with the consent of the
other Party, such consent not to be unreasonably withheld, except that a Party
may make such announcement or disclosure to the extent that such public
disclosure of the event or occurrence is, in the belief of counsel to the Party,
required by Applicable Law.

      10.4 RETURN OF CONFIDENTIAL INFORMATION. Upon termination or expiration of
the Agreement, or upon written request of the Disclosing Party, a Receiving
Party will promptly return to the Disclosing Party or destroy all documents,
notes and other tangible materials comprising or containing the Disclosing
Party's Confidential Information and all copies thereof; provided, however, that
each Party may retain a single archival copy of the other Party's Confidential
Information for the sole purpose of facilitating compliance with the surviving
provisions of this Agreement. Notwithstanding the foregoing, Altus may retain
copies of Lonza Technology or Developed Technology to the extent needed to
continue to exercise any license rights granted to Altus that survive
termination.

      10.5 EMPLOYEES; AGENTS. Each Party shall ensure that each employee,
consultant, or other agent of it, or of its Affiliates, who has access to
Confidential Information is bound to obligations of confidentiality and non-use
at least equivalent in scope to those set forth in Sections 9.1 and 9.2.

                                   ARTICLE 11

                                TERM AND TERMINATION

      11.1 TERM. This Agreement shall commence on the Effective Date and shall
continue for an initial term lasting until expiration on December 31, 2012, and
such term of the Agreement shall automatically renew thereafter for successive
two (2) year periods unless the Agreement is terminated by Altus with twelve
(12) months written notice prior to the expiration of such initial term or any
renewal period thereof, but subject to earlier termination of the Agreement as
provided below, (such term of the Agreement, the "TERM").

      11.2 TERMINATION FOR MATERIAL BREACH. A Party shall have the right to
terminate this Agreement upon written notice if the other Party material
breaches this Agreement and such breaching Party fails to cure such breach
within [***] following written receipt of such notice from the non-breaching
Party specifying such breach. Further, if at any time Lonza fails to deliver on
a timely basis material amounts of Bulk Product Component ordered by Altus under
one or more Purchase Orders because: (a) the applicable Lonza Facility does not
have the necessary licenses and thus Lonza cannot manufacture such Bulk Product
Component, and/or (b) Lonza's failure of regulatory compliance (as defined in
the Quality Agreement), then, on notice from Altus, Lonza [***] such failure and
shall cooperate in good faith with Altus in seeking to achieve such

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      41.
<PAGE>

cure [***], but if such failure is not completely cured [***] such notice, Altus
shall have the right to terminate this Agreement immediately on written notice.

      11.3 TERMINATION BY ALTUS.

         Altus shall have the right to terminate this Agreement on [***] prior
written notice if Altus determines that it will [***] or [***] of Final Products
due to [***] provided that if upon such termination date the total Transfer
Price owed and/or paid by Altus (the [***]), for the aggregate Batches ordered
by Altus in the Annual Order for [***] and in all additional Purchase Orders (if
any) submitted during [***] for manufacture during [***], is less than CHF
[***], and Altus has not purchased additional Batches at the [***] Transfer
Prices as required by Section 6.2(c), then Altus shall pay to Lonza, within
[***] of such termination, an amount equal to the difference between (i) CHF
[***], and the sum of (x) such [***], and (y) [***] for all Batches purchased by
Altus (under Section) after [***] at the [***].

      11.4 TERMINATION BY LONZA. Lonza shall have the right to terminate this
Agreement on [***] written notice to Altus either: (a) as provided in Section
3.5(f), or (b) if due to the material, uncured failure of Altus to provide, or
arrange for [***] to provide, to Lonza such materials controlled by [***] as are
necessary for Lonza to manufacture the Bulk Product Components, which failure
continues for [***] after written notice thereof from Lonza, Lonza has been
unable to manufacture any of the Bulk Product Components as contemplated in
Section 3.3(a) according to the agreed schedule for such manufacturing. If Lonza
terminates this Agreement under this Section 11.4, then Lonza shall within [***]
of the effective date of such terminate pay to Altus [***] U.S. dollars [***]
(as repayment of the amounts paid earlier by Altus with regards to [***], as
noted in Section 2.3).

      11.5 CANCELLATION OF BINDING ORDERS. Altus may cancel the manufacture and
supply of particular Batches of Bulk Product Component that have been ordered
under binding Purchase Orders, by written notice to Lonza, provided that Altus
shall remain obligated to pay the applicable Transfer Price for such all Batches
ordered, except as set forth in the following:

            (a) if Altus engages Lonza to manufacture other Altus products in
the same Lonza Facility as would have been used to manufacture such cancelled
Batches, during the same time as would have been used by Lonza to manufacture
such cancelled Batches, then Altus shall not pay the Transfer Price for such
cancelled Batches but shall pay the transfer price for such Altus products
manufactured by Lonza during at least part of such time, which transfer price
shall not in any event be less than the Transfer Price applicable to such
cancelled Batches;

            (b) if instead Altus provides to Lonza a third party customer that
is willing to engage Lonza to manufacture products for such customer in the same
Lonza Facility as would have been used to manufacture such cancelled Batches,
during at least part of the same time as would have been used by Lonza to
manufacture such cancelled Batches, then Altus shall only pay to Lonza an amount
equal to: (x) the [***]; less (y)

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      42.
<PAGE>

the [***] (the "3rd Party Purchase Price"); plus (z) [***] such 3rd Party
Purchase Price (but not to exceed [***] of the amount in subclause (x) above);
and

            (c) if instead Lonza identifies a third party customer that is
willing to engage Lonza to manufacture products for such customer in the same
Lonza Facility as would have been used to manufacture such cancelled Batches,
during at least part of the same time as would have been used by Lonza to
manufacture such cancelled Batches, then Altus shall only pay to Lonza an amount
equal to: (x) the total [***]; less (y) the [***]; plus (z) [***] of such 3rd
Party Purchase Price (but not in any event to exceed [***] of the amount in
subclause (x) above).

      11.6 TERMINATION FOR BANKRUPTCY. A Party shall have the right to terminate
this Agreement by written notice immediately upon the occurrence of either of
the following: (a) the entry of a decree or order for relief by a court having
jurisdiction in the premises in respect of the other Party in an involuntary
case under any applicable national, federal, or state insolvency or other
similar law, and the continuance of any such decree or order unstayed and in
effect for a period of [***] or (b) the filing by the other Party of a petition
for relief under any applicable national, federal, or state insolvency or other
similar law.

      11.7 SURVIVING OBLIGATIONS. Termination or expiration of this Agreement
shall not (a) affect any other rights of either Party which may have accrued up
to the date of such termination or expiration or (b) relieve Altus of its
obligation to pay to Lonza sums due in respect of Bulk Product Component
delivered prior to termination or expiration of this Agreement (subject to
Altus' acceptance pursuant to Section 3.5). The provisions of Sections 3.10,
3.11, 3.17, 5.10, 11.7, and Articles 1, 7 (excluding Section 7.1), 8, 9, 10, and
12 shall survive the termination or expiration of this Agreement for the longer
of a period of five (5) years, or as long as such provisions remain applicable
to the remaining rights and obligations of the Parties.

                                   ARTICLE 12

                                  GENERAL TERMS

      12.1 USE OF NAME. No right, express or implied, is granted by this
Agreement to either party to use in any manner the name of the other or any
other trade name or trademark of the other in connection with the performance of
this Agreement, except as required by law, including without limitation
securities laws.

      12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER
PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES
ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY
NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS UNDER SECTION 9.1 or 9.2, OR DAMAGES AVAILABLE FOR
BREACHES OF

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      43.
<PAGE>

CONFIDENTIALITY OBLIGATIONS IN ARTICLE 10. The limitations on
liability and exclusion of damages under this Agreement: (i) apply even if Altus
had or should have had knowledge, actual or constructive, of the possibility of
such damages; (ii) are a fundamental element of the basis of the bargain between
the parties and this Agreement would not be entered into without such
limitations and exclusions and (iii) shall apply whether a claim is based on
breach of contract, breach of warranty, tort (including negligence), product
liability, strict liability or otherwise, and notwithstanding any failure of
essential purpose of any limited remedy herein. Moreover, the limitations of
liability and the exclusion of damages under this Agreement are intended to
apply even if there is a total and fundamental breach of this Agreement, and the
essential purpose of these provisions is to limit the parties' respective
liabilities hereunder.

      12.3 INDEPENDENT PARTIES. Neither Party is an employee, partner, joint
venturer or legal representative of the other Party for any purpose. Neither
Party shall have the authority to enter into any contracts in the name of or on
behalf of, or otherwise bind, the other Party.

      12.4 GOVERNING LAW. This Agreement is made in accordance with and shall be
governed and construed under the federal and state laws of England and Wales,
without regard to any conflicts of law principles that would provide for
application of the laws of another jurisdiction.

      12.5 DISPUTE RESOLUTION.

            (a) The Parties will use all reasonable and good faith efforts to
resolve any disputes or issues arising out of this Agreement. The Parties shall
refer any such dispute or issue to the Vice President of Sales & Business
Development of Lonza and the Senior Vice President of Manufacturing and
Technical Operations of Altus, who shall co-operate and discuss the matter in
good faith and seek to resolve the dispute or issue as amicably as possible
within [***] of the dispute being referred to them.

            (b) For any dispute or issue under the Agreement that is not
resolved by the procedure described in Section 12.5(a) above (although the
Parties agree that such procedures do not preclude either Party from applying to
the court for interim relief), such dispute or issue between the Parties arising
under, out of or relating to this Agreement or arising out of the circumstances
and relationships contemplated by this Agreement including disputes relating to
the validity, construction, interpretation or enforcement of this Agreement and
including its formation, validity, binding effect, interpretation, performance,
breach or termination as well as non-contractual claims and including disputes
relating to pre-contractual representations (collectively, "Disputes), shall be
resolved by binding arbitration as provided in the following:

            (c) Either Party may submit any such unresolved Dispute to be
finally settled by arbitration, which shall be conducted and administered by the
International Commerce Commission in accordance with its rules for arbitration
of commercial disputes, plus the rules of evidence and discovery as provided in
the Federal Rules of Civil Procedure in the United States (and any additional
provisions or rules as the Parties

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      44.

<PAGE>

may agree in writing), (collectively, the "Rules"). Such arbitration shall be
conducted in New York City, New York (or such other location as the Parties may
agree) in accordance with the Rules, and as such Rules may be amended by the
Parties in writing from time to time. The arbitration shall be conducted by
three (3) arbitrators, one arbitrator to be appointed by Lonza, one arbitrator
to be appointed by Altus, and the presiding arbitrator to be appointed by such
two arbitrators. Each such arbitrator must be neutral, independent and totally
unaffiliated with either Party or any of its Affiliates, and must have
significant experience in the drafting and enforcement of licensing contracts
in the pharmaceutical industry.

            (d) All decisions of the arbitrators shall be final, binding and
conclusive on the Parties (absent manifest fraud) and shall constitute the only
method of resolving disputes or matters subject to arbitration. The arbitrators
shall be authorized to award compensatory damages, but shall NOT be authorized
to award non-economic damages, punitive damages, or to reform, modify or
materially change this Agreement or any other agreements contemplated hereunder.
The arbitrators or a court of appropriate jurisdiction may issue a writ of
execution to enforce the arbitrators' judgment. Judgment may be entered upon
such a decision in accordance with applicable law in any court having
jurisdiction thereof.

            (e) Any action or proceeding to enforce an arbitration decision, or
to proceed for interim equitable relief, shall be subject to the non-exclusive
jurisdiction of the federal courts in New York City, New York and the Courts of
England and Wales.

    12.6 NOTICE. Any notice or other communication or payment herein required or
permitted to be given shall be deemed sufficient if and when personally
delivered in writing, or if and when given by an international overnight courier
(with signature release) or by United States registered or certified mail,
postage prepaid, return receipt requested, in either case properly addressed to
the respective addresses of a Party as written below. Notices so given shall be
effective upon the earlier to occur of (i) receipt by the party to which notice
is given, or (ii) the [***] business day following the date such notice was
posted, whichever occurs first. All notices, including notices of address
change, required or permitted to be given under this Agreement shall be in
writing and sent by overnight courier with proof of delivery, in each case
addressed to:

            In the case of Altus:

                  Altus Pharmaceuticals Inc.
                  125 Sidney Street
                  Cambridge, MA 02139-4807
                  Attention:  Chief Executive Officer

            With a required copy to:

                  Altus Pharmaceuticals Inc.
                  125 Sidney Street
                  Cambridge, MA 02139-4807
                  Attention:  Legal Department

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      45.

<PAGE>

            In the case of Lonza:

                  Lonza Inc.
                  25 Commerce Drive
                  Allendale, NJ 07401
                  Attention:  VP of Sales and Business Development

            With required copy to:

                  Lonza Ltd
                  Muenchensteinerstrasse 38
                  CH-4002 Basel, Switzerland
                  Attention:  Head of Legal Affairs / Services

      12.7 SEVERABILITY. If any one or more of the provisions contained in this
Agreement is held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired thereby, unless the absence
of the invalidated provision(s) adversely affects the substantive rights of the
parties. The parties shall in such an instance use their best efforts to replace
the invalid, illegal or unenforceable provision(s) with valid, legal and
enforceable provision(s) which, insofar as practical, implement the purposes of
this Agreement.

      12.8 WAIVER. Any waiver (express or implied) by either party of any breach
of this Agreement shall not constitute a waiver of any other or subsequent
breach.

      12.9 ADDITIONAL FACILITIES. Lonza hereby [***] to engage Lonza to
manufacture Bulk Product Component in any new Lonza manufacturing facility or in
any [***] by Lonza (or its Affiliate), during the Term that is appropriate for
manufacturing such Bulk Product Component. Altus agrees that, if Lonza builds or
acquires additional manufacturing capacity (i.e, beyond the existing
manufacturing capacity for Bulk Product Components in the Lonza Facilities) that
is applicable and appropriate for manufacturing Bulk Product Component, Altus
shall [***] to place Purchase Orders (to the extent Altus requires additional
Batches and subject to the limitations in Section 3.18) for additional Batches
of Bulk Product Component to be manufactured in such additional capacity (i.e.,
beyond Lonza's existing manufacturing capacity in the applicable Lonza Facility
used to manufacture such Bulk Product Component).

      12.10 ENTIRE AGREEMENT. This Agreement and the Exhibits attached hereto
constitute the entire, final, complete and exclusive agreement between the
Parties and supersede all previous agreements or representations, written or
oral, with respect to the subject matter of this Agreement, and the Letter of
Intent and the Tech Transfer

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      46.

<PAGE>

Agreement are hereby terminated and superseded by this Agreement.
Notwithstanding the foregoing, this Agreement does not supersede the
Confidentiality Agreement, which shall continue in full force and effect in
accordance with its terms. This Agreement may not be modified or amended except
in a writing signed by a duly authorized representative of each Party.

      12.11 NON-ASSIGNABILITY; BINDING ON SUCCESSORS. Neither Party may assign
or delegate this Agreement or any obligation hereunder without the prior written
consent of the other Party, such consent not to be unreasonably withheld;
provided, however, that a Party may assign this Agreement without such consent
to its Affiliate, or to its successor in interest in connection with any merger,
consolidation, or sale of all or substantially all of the assets of such Party.
In the case of any permitted assignment or transfer of or under this Agreement,
this Agreement shall be binding upon, and inure to the benefit of, the
successors, executors, heirs, representatives, administrators and assigns of the
parties hereto, and any successor to Lonza shall agree in writing to be so bound
and to supply all Bulk Product Components to Altus as ordered under the terms of
this Agreement. Any attempted assignment of the rights or delegation of the
obligations under this Agreement in violation of the above restrictions shall be
void.

      12.12 CONSTRUCTION. Except where the context otherwise requires, wherever
used, the singular will include the plural, the plural the singular, and the use
of any gender will be applicable to all genders. Unless used in combination with
the word "either," the word "or" is used throughout this Agreement in the
inclusive sense (and/or). Unless expressly provided otherwise, references to
Sections are references to Sections of this Agreement. The captions of this
Agreement are for convenience of reference only and in no way define, describe,
extend or limit the scope or intent of this Agreement or the intent of any
provision contained in this Agreement. The term "including" as used in this
Agreement will mean "including without limitation" and shall not be construed to
limit the generality of any description preceding such term. No rule of strict
construction will be applied against either party. Unless expressly provided in
this Agreement to the contrary, all time limits, notice periods, deadlines or
the like described in this Agreement will be governed by the follow parameters:
(i) for all time periods that are 5 days in length or less, such periods will be
deemed to be business days in the State of New York, and (ii) for all time
periods greater than 5 days in length will be deemed to be calendar days.

      12.13 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which shall
constitute together the same instrument.

                            Signature Page to Follow

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      47.
<PAGE>

      IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to
be signed and delivered by its duly authorized officer or representative as of
the date first set forth above.

ALTUS PHARMACEUTICALS INC.                        LONZA LTD

By:                                        By:
      -----------------------------              -------------------------------

Name:                                      Name:
      -----------------------------              -------------------------------

Title:                                     Title:
      ----------------------------               ------------------------------

              Signature Page to Manufacturing and Supply Agreement

                                                              Execution Original

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
 CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                      48.

<PAGE>

                                    EXHIBIT A
                             BULK PRODUCT COMPONENTS

The "Bulk Product Components" that LONZA will produce under this Agreement are
the three different enzyme drug substances listed below:

Amylase

Lipase-CLEC

Protease

These bulk drug substances are produced by [***] [***] according to processes
proprietary to ALTUS as indicated in technology transfer documents.

[***] will be provided to LONZA.

[***] are listed below.

<TABLE>
<CAPTION>
                           AMYLASE    LIPASE    PROTEASE
<S>                        <C>       <C>        <C>
Organism                    [***]     [***]      [***]
Cell Line Description       [***]     [***]      [***]
Classification              [***]     [***]      [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
<PAGE>

                                    EXHIBIT B

                               BULK SPECIFICATIONS

Bulk Product Component delivered to Altus or its designee will meet the
applicable of the following specifications:

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                  EXHIBIT B & H
                   DRAFT SPECIFICATIONS AND STABILITY STUDIES

DRAFT SPECIFICATIONS:

Draft Specifications must be agreed upon by both parties to become official
specifications.

Stability Studies:

LONZA will do stability testing for [***] engineering and validation Batches, as
well as for [***] for all three Bulk Product Components. Proposed stability
testing for all assays is as listed in the Table below.

Stability testing will be done [***] as indicated below

Assumed Stability Testing [***]

Assumed Stability Testing [***]
                          [***]
[***] analytical reports will be provided to ALTUS.

Details of the Stability Study design will be agreed upon between LONZA and
ALTUS prior to execution.

In additions [***] should be done including

      - [***]

      - [***]

      - [***]

Assays to include

      - [***]

      - [***]

      - [***]

      - [***]

        [***]

   Deliverables by Lonza to Altus:

      - [***]

      - [***]

      - [***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                  EXHIBIT B & H
                   DRAFT SPECIFICATIONS AND STABILITY STUDIES

      ALTU-135 API DRAFT RELEASE AND STABILITY TESTING FOR DRUG SUBSTANCE

      TABLE 1. DRAFT LOT RELEASE SPECIFICATIONS FOR AMYLASE DRUG SUBSTANCE

<TABLE>
<S>                                     <C>
Handling and Storage                    [***]

Size/ Packaging                         [***]
</TABLE>

<TABLE>
<CAPTION>
     ATTRIBUTE               TEST DESCRIPTION        METHOD        ACCEPTANCE CRITERIA         USE
<S>                          <C>                     <C>           <C>                        <C>
     Safety                       [***]              [***]               [***]                [***]
     Potency                      [***]              [***]               [***]                [***]
     Quality                      [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
     Purity                       [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
 Characterization                 [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                 EXHIBIT B & H
                   DRAFT SPECIFICATIONS AND STABILITY STUDIES

              [***]              [***]               [***]                [***]

[***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                  EXHIBIT B & H
                   DRAFT SPECIFICATIONS AND STABILITY STUDIES

     TABLE 2. DRAFT LOT RELEASE TESTING METHODS FOR PROTEASE DRUG SUBSTANCE

<TABLE>
<S>                                      <C>
 Handling and Storage                    [***]

 Size/ Packaging                         [***]
</TABLE>

<TABLE>
<CAPTION>

     ATTRIBUTE               TEST DESCRIPTION        METHOD        ACCEPTANCE CRITERIA         USE
<S>                          <C>                     <C>           <C>                        <C>
     Safety                       [***]              [***]               [***]                [***]
     Potency                      [***]              [***]               [***]                [***]
     Quality                      [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
     Purity                       [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
 Characterization                 [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
</TABLE>

[***]
                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                 EXHIBIT B & H
[***]             DRAFT SPECIFICATIONS AND STABILITY STUDIES

   TABLE 3. DRAFT LOT RELEASE TESTING METHODS FOR LIPASE-CLEC DRUG SUBSTANCE

<TABLE>
<S>                                      <C>
 Handling and Storage                    [***]

 Size/ Packaging                         [***]
</TABLE>

<TABLE>
<CAPTION>
     ATTRIBUTE               TEST DESCRIPTION        METHOD        ACCEPTANCE CRITERIA         USE
<S>                          <C>                     <C>           <C>                       <C>
     Safety                       [***]              [***]               [***]                [***]
     Potency                      [***]              [***]               [***]                [***]
     Quality                      [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
     Purity                       [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
 Characterization                 [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
                                  [***]              [***]               [***]                [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                      EXHIBIT B & H
                   DRAFT SPECIFICATIONS AND STABILITY STUDIES

                                                    [***]                [***]

[***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
<PAGE>

                                    EXHIBIT C

                         FORM OF CERTIFICATE OF ANALYSIS

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

Altus Pharmaceuticals Inc.                     Document Number: 000xxxx VER. 01
Document Status: DRAFT                                       Effective Date: NA

Title:
Part Number(s): xxxxxx

                     EXAMPLE DRAFT- CERTIFICATE OF ANALYSIS

1.0  BATCH INFORMATION

<TABLE>
<S>                         <C>
Product Name/Product        [***]
Part Number

Batch/Lot                   [***]

Manufacture Date            [***]

Active Source /Site
Packaging and Storage       [***]
Shipping                    [***]
Expiration/Retest           [***]
</TABLE>

2.0  TEST RESULTS

<TABLE>
<CAPTION>
DESCRIPTION              REFERENCE /     SPECIFICATION / CRITERIA   TEST RESULT
                          METHOD
<S>                     <C>              <C>                        <C>
[***]                      [***]                   [***]
[***]                                              [***]
[***]                                              [***]
[***]                                              [***]
[***]                                              [***]
</TABLE>

3.0  APPROVALS

<TABLE>
<CAPTION>
DEPARTMENT                      SIGNATURE                      DATE
<S>                             <C>                            <C>
Quality Control:
</TABLE>

       CONFIDENTIAL INFORMATION - DO NOT REPRODUCE WITHOUT AUTHORIZATION

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

Altus Pharmaceuticals Inc.                     Document Number: 000xxxx VER. 01
Document Status: DRAFT                                       Effective Date: NA

Title:
Part Number(s): xxxxxx

                        DOCUMENT MANAGEMENT INFORMATION

DATE SENT FOR APPROVAL
SUPERSEDES                                                          [***]
LOCATION                                                            [***]
DESCRIPTION OF CHANGE/REASON FOR CHANGE
[***]
COMMENTS
NA

       CONFIDENTIAL INFORMATION - DO NOT REPRODUCE WITHOUT AUTHORIZATION

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                                  PAGE 2 OF 3
<PAGE>

Altus Pharmaceuticals Inc.                     Document Number: 000xxxx VER. 01
Document Status: DRAFT                                       Effective Date: NA

Title:
Part Number(s): xxxxxx

<TABLE>
<CAPTION>
                                    APPROVALS
FUNCTION/DEPT           CODE           NAME         SIGNATURE        DATE
<S>                     <C>         <C>           <C>               <C>
WRITER/REVISER          [***]                     xxxxxxxxxxxxxx    xxxxxxx
QUALITY ASSURANCE       [***]                     xxxxxxxxxxxxxx    xxxxxxx
</TABLE>

       Confidential Information - Do Not Reproduce Without Authorization

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                                  Page 3 of 3
<PAGE>

                                    EXHIBIT D

                            TECHNOLOGY TRANSFER PLAN

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT D
                              TECHNOLOGY TRANSFER

The processes for the production of each Bulk Product Component (Amylase,
Protease, and Lipase-CLEC) will be transferred [***] to Lonza ([***]) with the
assistance of Altus Pharmaceuticals. In order to execute such technology
transfer, [***] Lonza (via Altus) with [***] [***]

During the initial phase of the technology transfer, complex [***] [***] will be
provided by [***] Lonza will use these [***] to [***]. If Lonza decides to
eventually source these complex [***] from another source a [***]

Transfer of Analytical methods is also a major part of the technology transfer.
Most methods will be transferred [***] The methods will be supplied to Lonza in
English. [***] will be transferred [***] [***]

The technology transfer will be considered successful when [***][***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                    EXHIBIT D
                              TECHNOLOGY TRANSFER

[***]

<TABLE>
<CAPTION>
                       KG                    KG                  KG
                     AMVLASE            LIPASE(CLEC)          PROTEASE
<S>                  <C>                <C>                   <C>
[***]                 [***]                [***]               [***]
                                           [***]
[***]                 [***]                [***]               [***]
[***]                 [***]                [***]               [***]
[***]                 [***]                [***]               [***]
[***]                 [***]
</TABLE>

AMYLASE NOTE: The [***] was based upon [***].[***]has been [***] the drug
substance and [***] provided to Lonza. The[***] [***]

     Lonza shall provide the following Deliverables to Altus as part of the
     technology transfer process:

          -    [***]

          -    [***]

          -    [***]

          -    [***]Altus Pharmaceuticals.

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
<PAGE>

                                   EXHIBIT D
                              TECHNOLOGY TRANSFER

        Lonza shall take and analyze the following in-process and process
            monitoring samples for tech transfer based on the [***]:

                                      [***]

                   AMALAYSE IN-PROCESS AND PROCESS MONITORING
<TABLE>
<CAPTION>
#         PROCESS STEP           IN-PROCESS TEST             PROCESS MONITORING
<S>       <C>                    <C>                         <C>
  1         [***]                  [***]                          [***]

  2         [***]                  [***]                          [***]

  3         [***]                  [***]                          [***]

  4         [***]                                                 [***]

  5         [***]                                                 [***]

  6         [***]                                                 [***]

  7         [***]                  [***]                          [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                    EXHIBIT D
                              TECHNOLOGY TRANSFER

                    AMALAYSE IN-PROCESS AND PROCESS MONITORING
<TABLE>
<CAPTION>
#              PROCESS STEP        IN PROCESS TEST      PROCESS MONITORING
<S>            <C>                 <C>                  <C>
   8             [***]               [***]               [***]

   9             [***]

   10            [***]               [***]               [***]

   11            [***]               [***]               [***]

   12            [***]                                   [***]

   13            [***]               [***]               [***]

   14            [***]               [***]               [***]

   15            [***]               [***]               [***]

   16            [***]
</TABLE>

---------------
*     Not Necessary for Laboratory Studies for Tech Transfer

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

PROTEASE DRUG SUBSTANCE IN-PROCESS AND PROCESS MONITORING TESTS

                   PROTEASE IN-PROCESS AND PROCESS MONITORING
<TABLE>
<CAPTION>
#           Process Step         In-Process Tests         Process Monitoring
<S>         <C>                  <C>                      <C>
 1             [***]               [***]                       [***]

 2             [***]               [***]                       [***]

 3             [***]               [***]                       [***]

 4             [***]               [***]                       [***]

 5             [***]                                           [***]

 6             [***]                                           [***]

 7             [***]                                           [***]

 8             [***]               [***]                       [***]

 9             [***]               [***]                       [***]

 10            [***]

 11            [***]

 12            [***]               [***]                       [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Security Exchange Act of 1934.
<PAGE>

PROTEASE DRUG SUBSTANCE IN-PROCESS AND PROCESS MONITORING TEST

<TABLE>
<CAPTION>
                PROTEASE IN-PROCESS AND PROCESS MONITORING
#        PROCESS STEP     IN-PROCESS TESTS     PROCESS MONITORING
<S>      <C>              <C>                  <C>
                               [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

PROTEASE DRUG SUBSTANCE IN-PROCESS AND PROCESS MONITORING TEST

<TABLE>
<S>          <C>          <C>                        <C>
13           [***]        [***]                      [***]
14           [***]        [***]                      [***]
15           [***]
16           [***]        [***]                      [***]
17           [***]
17           [***]        [***]
18           [***]
</TABLE>

----------
*   Not Necessary for Laboratory Studies for Tech Transfer

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

PROTEASE DRUG SUBSTANCE IN-PROCESS AND PROCESS MONITORING TEST

<TABLE>
<CAPTION>
                 LIPASE IN-PROCESS AND PROCESS MONITORING
#        PROCESS STEP     IN-PROCESS TESTS         MONITORING
<S>      <C>              <C>                      <C>
1            [***]             [***]                 [***]
2            [***]             [***]                 [***]
3            [***]             [***]                 [***]
4            [***]             [***]                 [***]
5            [***]             [***]
6            [***]                                   [***]
7            [***]                                   [***]
8            [***]             [***]                 [***]
9            [***]             [***]                 [***]
10           [***]             [***]
11           [***]             [***]                 [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

PROTEASE DRUG SUBSTANCE IN-PROCESS AND PROCESS MONITORING TEST

<TABLE>
<CAPTION>
                 LIPASE IN-PROCESS AND PROCESS MONITORING
#        PROCESS STEP     IN-PROCESS TESTS         MONITORING
<S>      <C>              <C>                      <C>
         [***]                                       [***]
12       [***]                 [***]                 [***]
13       [***]                 [***]                 [***]
14       [***]                 [***]                 [***]
15       [***]                 [***]                 [***]
16       [***]                 [***]                 [***]
17       [***]
</TABLE>

----------
*   Not Necessary for Laboratory Studies for Tech Transfer

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
<PAGE>

                                    EXHIBIT E

                              DESIGNATED EQUIPMENT

LONZA CAPITAL EQUIPMENT COMMITMENT

Lonza will provide [***] necessary to manufacture the three Bulk Product
Components. This includes the purchase of [***] items not already available in
the facility such as, but is not limited to, the following major pieces of
process equipment:

      [***]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT F

                               VALIDATION STUDIES

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT F
                       VALIDATION AND ENGINEERING STUDIES

      Lonza will conduct [***] engineering Batch for each Drug Substance Bulk
      Product Component, followed by at least [***] process validation Batches
      for each Bulk Product Component, with each of such [***] Batches meeting
      the pre-agreed validation acceptance criteria.

      Such validation Batches will meet the applicable Bulk Specifications and
      be suitable for commercial supply.

      Details of the validation study design will be agreed upon between Lonza
      and Altus prior to execution.

      Deliverables

            - [***]

            - [***]

            - [***]

            - [***]

            - [***]

            - [***] Altus [***] Lonza [***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>
                                     EXHIBIT G

                        PROCESS LIMITS EVALUATION STUDIES

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT G
                        PROCESS LIMITS EVALUATION STUDIES

Critical steps in the production processes for each of the Bulk Product
Component are [***]

Process Characterization laboratory studies are to be performed by Lonza to
support the production processes for each of the Drug Substance Bulk Product
Components ( protease, amylase, and lipase) used in producing the ALTU-135 final
product. In this [***]

Preliminary tables identifying the [***] can be found in the table set forth
below in this Exhibit G. Studies are to be performed by Lonza [***] will be used
for these studies to evaluate [***][***][***] Lonza defining [***] in the [***]
All studies are excepted to be performed [***][***].

This information may be modified by [***] which are currently [***] [***].

Lonza Deliverables to Altus:

      - [***]

      - [***]

      - [***]

      - [***] Altus Pharmaceuticals.

      - [***] Altus [***] [***]

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                    EXHIBIT G
                        PROCESS LIMITS EVALUATION STUDIES

                          ALTU-135 CRITICAL PARAMETERS

CRITICAL STEPS IN AMYLASE PRODUCTION PROCESS (PRELIMINARY)

<TABLE>
<CAPTION>
CRITICAL STEP                  PARAMETERS TO BE STUDIED DURING PROCESS CHARACTERIZATION
                                  INPUT PARAMETERS                 OUTPUT PARAMETERS(1)
<S>                               <C>                              <C>
    [***]                              [***]                            [***]

    [***]                              [***]                            [***]

    [***]                              [***]                            [***]

    [***]                              [***]                            [***]

    [***]                              [***]                            [***]
</TABLE>

[***]

CRITICAL STEPS IN LIPASE CLEC PRODUCTION PROCESS (PRELIMINARY)

<TABLE>
<CAPTION>
CRITICAL STEP                PARAMETERS TO BE STUDIED DURING PROCESS CHARACTERIZATION
                                   INPUT PARAMETERS                 OUTPUT PARAMETERS
<S>                                <C>                              <C>
[***]                              [***]                            [***]

[***]                              [***]                            [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                    EXHIBIT G
                       PROCESS LIMITS EVALUATION STUDIES
<TABLE>
<S>                                       <C>                                    <C>
[***]                                     [***]                                  [***]

[***]                                     [***]                                  [***]

[***]                                     [***]                                  [***]

[***]                                     [***]                                  [***]
</TABLE>

[***]

CRITICAL STEPS IN THE PROTEASE PRODUCTION PROCESS (PRELIMINARY)

<TABLE>
<CAPTION>
CRITICAL STEP                    PARAMETERS TO BE STUDIED DURING PROCESS CHARACTERIZATION
                                 INPUT PARAMETERS                    OUTPUT PARAMETERS(1)
<S>                              <C>                                 <C>
[***]                                  [***]                               [***]

[***]                                  [***]                               [***]

[***]                                  [***]                               [***]

[***]                                  [***]                               [***]

[***]                                  [***]                               [***]
</TABLE>

                                      CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

                                   EXHIBIT G
                       PROCESS LIMITS EVALUATION STUDIES

                [***]

[***]           [***]           [***]

[***]           [***]           [***]

[***]

                                     CONFIDENTIAL TO ALTUS PHARMACEUTICALS INC.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
<PAGE>

                                    EXHIBIT H

                                STABILITY STUDIES

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT I

                                 TRANSFER PRICES

                               (ALL PRICES IN CHF)

TABLE 1.

<TABLE>
<CAPTION>
ENZYME                              PRICE (CHF)
---------------    -------------------------------------------------------------
<S>                <C>
                          [***] ENGINEERING AND VALIDATION

Lipase, Protease   [***] Batches of each enzyme, includes validation campaign
  and Amylase            support fees

                                           [***]

                                     [***]

          Lipase                     [***] Batches:
                                     [***] PER BATCH

        Protease                     [***] Batches:
                                     [***] PER BATCH

         Amylase                     [***] Batches:
                                     [***] PER BATCH
</TABLE>

-     The prices above in Table 1 applies for the cumulative purchase for Lipase
      of [***] Batches in [***] and (if applicable) [***], for Protease of [***]
      Batches in [***] and (if applicable) [***], and for Amylase of [***]
      Batches in [***] and (if applicable) [***]. Any additional Batches
      purchased by Altus (beyond the foregoing numbers of Batches) shall be at
      the applicable Transfer Prices set forth below.

-     The prices above in Table 1 are Batch prices. [***] costs shall only be
      charged if there is a [***]initiated for a particular Bulk Product
      Component in [***] or [***] (which is not intended or anticipated)

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

TABLE 2.

                  CAMPAIGN PRICE = ([***]) + ([***]) + ([***])

THEREIN: N = TOTAL NUMBER OF ORDERED BATCHES

LONZA MAY INCLUDE [***] FOR THE NUMBER OF [***] THAT WERE [***] TO [***] THE
APPLICABLE FACILITY IN ORDER TO [***], BUT PROVIDED THAT SUCH NUMBER SHALL NOT
IN ANY EVENT EXCEED [***] TOTAL.

            TRANSFER PRICES IN CHF, FOR BATCHES MANUFACTURED IN [***]
  (for [***] Batches of Lipase, [***] Batches of Protease and [***] Batches of
        Amylase after completion of [***] requirements, if any, in [***])

TABLE 2A.

<TABLE>
<CAPTION>
                                 PRICE OF [***]
 ENZYME      PRICE [***]             [***]            [***]
--------   ---------------   -------------------     -----------
<S>        <C>               <C>                     <C>
Lipase         [***]                 [***]            [***]

Protease       [***]                 [***]            [***]

Amylase        [***]                 [***]            [***]
</TABLE>

            TRANSFER PRICES IN CHF, FOR BATCHES MANUFACTURED IN [***]
 (for any additional batches manufactured in [***] in excess of requirements in
  Table 1, if any, and Table 2a. as well as for Batches manufactured in [***])

TABLE 2B.

<TABLE>
<CAPTION>

 ENZYME      PRICE [***]         PRICE OF [***]     [***]DAY
                                     [***]
--------   ---------------   -------------------   -----------
<S>        <C>               <C>                   <C>
Lipase        [***]                [***]              [***]

Protease      [***]                [***]              [***]

Amylase       [***]                [***]              [***]
</TABLE>

-     The formula in Table 2, with pricing from Table 2a, defines the price for
      campaigns in [***], provided completion of Batch purchase requirements
      from Table 1.

-     The formula in Table 2, with pricing from Table 2b, defines the price for
      campaigns in [***]. Please note if Batch purchase requirements are
      completed for Table 1 and Table 2a in [***], the subsequent batches will
      revert to Table 2b for remaining purchases in [***].

-     Prices for the Batches of Protease resulting from a particular campaign
      where such campaign was initiated directly upon [***] from a [***] to
      [***], or for Batches of Lipase resulting from a particular campaign where
      such campaign was initiated directly upon a [***] from a [***] to [***],
      will be adjusted [***] by a [***], to be agreed upon by the Parties after
      [***], due to the [***] of [***] in the Facility (such as, due to the
      [***] [***] time and cost).

-     All prices are campaign prices, even if campaign extends into the
      subsequent year.

      EXAMPLE 1:

      Purchase assumptions:

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

      -     Altus orders [***] Batches of lipase, [***] Batches of protease and
            [***] Batches of amylase in [***]

      -     Altus orders [***] Batches of lipase, [***] Batches of protease and
            [***] Batches of amylase in [***].

      -     [***] takes [***] days for each campaign

According to the pricing model set forth above, the following Transfer Prices
apply to the respective Batches supplied under the above orders:

[***]

ENZYME

<TABLE>
<CAPTION>
           # of Batches                                        Required Batches
           purchased [***]   Price per Batch   Total Price    Outstanding - [***]
--------   ---------------   ---------------   -----------    -------------------
<S>        <C>               <C>               <C>            <C>
Lipase          [***]             [***]         [***]               [***]

Protease        [***]             [***]         [***]               [***]

Amylase         [***]             [***]         [***]               [***]
</TABLE>

[***]

ENZYME

<TABLE>
<CAPTION>
           # of Batches         [***]Batch    [***] Pricing   Remaining Batches at
           purchased in [***]   Requirement    Requirement       [***] pricing
           ------------------   -----------   -------------   --------------------
<S>        <C>                  <C>           <C>             <C>
Lipase              [***]         [***]           [***]                [***]

Protease            [***]         [***]           [***]                [***]

Amylase             [***]         [***]           [***]                [***]
</TABLE>

Please note in this example that the total of Batches purchased in [***] is CHF
[***].

Lipase: The price for [***] is calculated as follows:

[***]

Protease: The price for [***] is calculated as follows:

[***]

[***]

Amylase: The price for [***] is calculated as follows:

[***]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

Total for [***] is CHF [***].

Please note in this example, as per contract, an interest fee of at [***] per
annum would also be payable to Lonza in [***] due to Altus not meeting the [***]
Batch purchase requirements totaling CHF [***] (i.e., total [***] for Batches
manufactured in [***] under binding Purchase Orders), which fee is calculated
based on [***] that the amount, equal to the difference between CHF [***] and
the actual [***], remains outstanding and unpaid.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

<PAGE>

                                    EXHIBIT J

                             FORM OF PURCHASE ORDER

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.
<PAGE>

                                    EXHIBIT J
                           FORM OF THE PURCHASE ORDER

                                                                 PURCHASE ORDER
[ALTUS LOGO]  Altus Pharmaceuticals, Inc    Purchase Order No.          004729
              125 Sidney Street:--                 Revision No.               0
              Cambridge MA 02139                           Date        8/1/2006
              Phone: (617) 295-2900                  Order Type   Regular Order
              Fax: (617) 299- 2999                    Vender Id          New 00

                                                      confirm #

To:                                             SHIP TO:
New vendor                                      Altus Pharmaceuticals, Inc
                                                Receiving Department
                                                625 Putnam Ave
                                                Cambridge MA 02139

                                                BILL TO:

                                                Altus Pharmaceuticals, Inc
                                                Accounts Payable
                                                125 Sidney, street
                                                Cambridge MA 02139

                                                                          PAGE 1

F.O.B POINT                     SHIP VIA                       BUYER

              ORDER DATE                           TERMS
               8/1/2006                           Net 30
<TABLE>
<CAPTION>
  LINE    PART NUMBER   DATE REQUIRED    REQUESTOR      REQ MBR    QUANTITY    UNITS   PRICE   EXT.PRICE
<S>     <C>             <C>              <C>            <C>        <C>         <C>     <C>     <C>
   1    EXAMPLE ONLY       8/1/2006        TEST           0123       1.00       EA               0.00
        Example-for Illustration purposes only.

                                                                                       TOTAL     0.00
</TABLE>

                                     Confidential to Altus Pharmaceuticals Inc.

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>
                                   Exhibit K
                                  Project Plan

                             [Gantt Chart Redacted]

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.Exhibit 10.1

 

EXHIBIT 10.1

Loan No. 3789055-101

TERM REVOLVING CREDIT AGREEMENT

          THIS TERM REVOLVING CREDIT AGREEMENT (“ Agreement”) is entered into as of January 31, 2007
and is a replacement of the Agreement” Dated October 5,
2006, between FARM CREDIT WEST, PCA,
Visalia, California (“FCW”) and CALAVO GROWERS,
INC., Santa Paula, California (the “Company”).

     SECTION
1. The Credit Facility. On the terms and conditions set forth in this Agreement, FCW
agrees to make advances to the Company during the period set forth below in an aggregate principal
amount not to exceed $12,000,000.00 (the “Commitment”). The Agreement and Commitment is executed,
delivered and accepted not in payment of but for the purpose of amending, restating and replacing
the following described obligations, and renewing any unpaid balance(s) evidenced thereby: Note
dated August 17, 2005, in the principal amount of $12,000,000.00. Furthermore, the Commitment also
evidences an additional loan advance(s) to the extent the Commitment under this Agreement exceeds
the renewed unpaid balance(s) referred to above.

     SECTION 2. Sale of Interest. The Company acknowledges that FCW has the option to participate
all or a portion of the Commitment with one or more lenders, including CoBank, ACB (“CoBank”). All
advances hereunder shall be made by CoBank as agent for FCW and all repayments by the Company
hereunder shall be made to CoBank as agent for FCW.

     SECTION 3. Purpose. The purpose of the Commitment is to finance the purchase and installation
of capital items and other corporate needs of the Company.

     SECTION 4. Term. The term of the Commitment shall be from the date hereof, up to and
including February 1. 2010.

     SECTION
5. Availability. Subject to the provisions of Section 25, advances will be made
available on any day on which FCW, CoBank, and the Federal Reserve Banks are open for business
upon the telephonic or written request of the Company. Requests for advances must be received no
later than 12:00 Noon, Company’s local time, on the date the advance is desired. Advances will be
made available by CoBank by wire transfer of immediately available funds to such account or
accounts as may be authorized by the Company. The Company shall furnish to CoBank a duly completed
and executed copy of a CoBank Delegation and Wire and Electronic Transfer Authorization Form, and
CoBank shall be entitled to rely on (and shall incur no liability to the Company in acting on) any
request or direction furnished in accordance with the terms thereof.

     SECTION 6. Interest and Fees.

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 2

     (A) Interest. The Company agrees to pay interest on the unpaid balance of the Commitment in
accordance with the following interest rate option:

          (1) 7-Day LIBOR Index Rate. At a rate (rounded upward to the nearest 1/100th% and adjusted for
reserves required on “Eurocurrency Liabilities” (as hereinafter defined) for banks subject to “FRB
Regulation D” (as hereinafter defined) or required by any other federal law or regulation) per
annum equal at all times to 100 basis points (1.00%) above the annual rate quoted by the British
Bankers Association (the “BBA”) at 11:00 a.m. London time for the offering of seven (7) day of U.S.
dollars deposits, as published by Bloomberg or another major information vendor listed on BBA’s
official website on the first U.S. Banking Day (as hereinafter defined) in each week with such rate
to change weekly on such day. The rate shall be reset automatically, without the necessity of
notice being provided to the Company or any other party, on the first U.S. Banking Day of each
succeeding week and each change in the rate shall be applicable to all balances subject to this
option and information about the then current rate shall be made available upon telephonic request.
For purposes hereof (a) “U.S. Banking Day” shall mean a day on which CoBank is open for business,
dealings in U.S. dollar deposits are being carried out in the London interbank market, and banks
are open for business in New York City and London, England; (b) “Eurocurrency Liabilities” shall
have meaning as set forth in “FRB Regulation D”; and (c) “FRB Regulation D” shall mean Regulation D
as promulgated by the Board of Governors of the Federal Reserve System, 12 CFR Part 204, as
amended.

          (2) LIBOR. At a fixed rate per annum equal to “LIBOR” (as hereinafter defined) plus 100 basis
points (1%). Under this option: (1) rates may be fixed for “Interest Periods” (as hereinafter
defined) of 1, 2, 3, 6, 9 or 12 months as selected by the Company; (2) amounts may be fixed in
increments of $100,000.00 or multiples thereof; (3) the maximum number of fixes in place at any
one time shall be 10; and (4) rates may only be fixed on a “Banking Day” (as hereinafter defined)
on 3 Banking Days’ prior written notice. For purposes hereof: (a) “LIBOR” shall mean the rate
(rounded upward to the nearest sixteenth) and adjusted for reserves required on “Eurocurrency
Liabilities” (as hereinafter defined) for banks subject to “FRB Regulation D” (as herein defined)
or required by any other federal law or regulation) quoted by the British Bankers Association (the
“BBA”) at 11:00 a.m. London time 2 Banking Days before the commencement of the Interest Period for
the offering of U.S. dollar deposits in the London interbank market for the Interest Period
designated by the Company; as published by Bloomberg or another major information vendor listed on
BBA’s official website; (b) “Banking Day” shall mean a day on which CoBank is open for business,
dealings in U.S. dollar deposits are being carried out in the London interbank market, and banks
are open for business in New York City and London, England; (c) “Interest Period” shall mean a
period commencing on the date this option is to take effect and ending on the numerically
corresponding day in the next calendar month or the month that is 2, 3, 6, 9 or 12 months
thereafter, as the case may be; provided, however, that: (i) in the event such ending day is not a
Banking Day, such period shall be extended to the next Banking Day unless such next Banking Day
falls in the next calendar month, in which case it shall end on the preceding Banking Day; and
(ii) if there is no numerically corresponding day in the month, then such period shall end on the
last Banking Day

 

 

			
	AGREEMENT NO. 3789055-301
	 	Page 3

in the relevant month; (d) “Eurocurrency Liabilities” shall have meaning as set forth in “FRB
Regulation D”; and (e) “FRB Regulation D” shall mean Regulation D as promulgated by the Board of
Governors of the Federal Reserve System, 12 CFR Part 204, as amended.

          The Company shall select, the applicable rate option at the time it requests a loan hereunder
and may, subject to the limitations set forth above, elect to convert balances bearing interest at
the 7-Day LIBOR Index Rate option to the LIBOR rate option. Upon the expiration of any fixed rate
period, interest shall automatically accrue at the 7-Day LIBOR Index Rate option provided for above
unless the amount fixed is repaid or fixed for an additional period in accordance with the terms
hereof. Notwithstanding the foregoing, rates may not be fixed in such a manner as to cause the
Company to have to break any fixed rate balance in order to pay any installment of principal. All
elections provided for herein shall be made telephonically or in writing and must be received by
12:00 Noon Company’s local time. Interest shall be calculated on the actual number of days each
loan is outstanding on the basis of a year consisting of 360 days and shall be payable monthly in
arrears by the 20th day of the following month or on such other day in such month as FCW shall
require in a written notice to the Company.

          (B) Commitment Fee. In consideration of the Commitment, the Company agrees to pay to FCW a
commitment fee on the average daily unused portion of the Commitment at the rate of 0.15% per
annum (calculated on a 360 day basis based on utilization, which is defined as outstanding
advances plus issued and outstanding letters of credit divided by the total available amount of
the Commitment), payable quarterly in arrears by the 20th day following each quarter. Such fee
shall be payable for each quarter (or portion thereof) occurring during the original or any
extended term of the Commitment.

     SECTION
7. Repayment and Maturity. The unpaid principal balance of the Commitment shall
mature and be due and payable on February 1, 2010 (the “Maturity Date”).

     SECTION 8. Promissory Note. The Company’s obligation to repay the Commitment shall be
evidenced by a promissory note in the form attached hereto as Exhibit A (“Note”).

     SECTION 9. Manner and Time of Payment. CoBank shall maintain a record of all loans, the
interest accrued thereon, and all payments made with respect thereto, and such record shall, absent
proof of manifest error, be conclusive evidence of the outstanding principal and interest on the
loans. All payments shall be made by wire transfer of immediately available funds, by check, or by
automated clearing house or other similar cash handling processes as specified by separate
agreement between the Company and CoBank. Wire transfers shall be made to ABA No. 307088754 for
advice to and credit of CoBank (or to such other account as CoBank may direct by notice). The
Company shall give CoBank telephonic notice no later than 12:00 Noon Company’s local time of its
intent to pay by wire and funds received after 3:00 p.m. Company’s local time shall be credited on
the next business day. Checks shall be mailed to CoBank, Department 167, Denver, Colorado
80291-0167 (or to such other place as CoBank may direct by notice). Credit for payment by check
will not be given until the later of: (a) the day on

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 4

which CoBank receives immediately available funds; or (b) the next business day after receipt of
the check all as set forth in the Servicing Agreement between Borrower, FCW, and CoBank in form
attached hereto as Exhibit B.

     SECTION 10. Capitalization. The Company has purchased a $1,000.00 stock investment under
FCW’s capitalization plan. The Company understands that FCW’s stock is at risk and that any
reference to “FCW equities” or to “stock or participation certificates required by Lender’s
bylaws” in any document, agreement or Loan Document shall mean the FCW stock investment described
herein.

     SECTION 11. Patronage. The Commitment is eligible for patronage under the plan and in
accordance with the provisions of FCW’s bylaws and its practices and procedures related to
patronage distribution and as set forth in Section 27.

     SECTION 12. Security. The Company’s obligations under this Agreement and the Note shall be
secured by a statutory first lien on all equity which the Company may now own or hereafter acquire
in FCW. With the exception of the security referenced in the preceding sentence, the Company’s
obligations under this Agreement and the Note shall be unsecured.

     SECTION 13. Conditions Precedent. FCW’s obligation to make advances hereunder is subject to
the condition precedent that FCW receive, in form and content satisfactory to FCW, each of the
following:

          (A) Agreement. A duly executed copy of this Agreement and all instruments and
documents contemplated hereby.

          (B) Evidence of Authority. Such certified board resolutions, evidence of incumbency,
and other evidence that FCW may require that this Agreement and the
Note have been duly authorized and executed.

          (C) Fees and Other Charges. All fees and other charges provided for herein.

          (D) Evidence of Insurance. Such evidence as FCW may require that the Company is
in compliance with Section 15(C) hereof

          (E) Event of Default. That no “Event of Default” (as defined in Section 18 hereof) or
event which with the giving of notice and/or the passage of time would become an Event of
Default hereunder (a “Potential Default”), shall have occurred and be continuing.

SECTION 14. Representations and Warranties.

     (A) Agreement. The Company represents and warrants to FCW that as of the date of
this Agreement:

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 5

          (1) Compliance. The Company and, to the extent contemplated hereunder, each
“Subsidiary” (as defined below), is in compliance with all of the terms of this Agreement, and
no Event of Default or Potential Default exists hereunder.

          (2) Subsidiaries. The Company has the following Subsidiaries: Calavo Foods,
Inc. (CFI); Maui Fresh International, Inc.; Calavo de Mexico S.A, de C.V.; and Calavo Foods de
Mexico S.A. de C.V, . For purposes hereof, a “Subsidiary” shall mean a corporation of which
shares of stock having ordinary voting power to elect a majority of the board of directors or
other
managers of such corporation are owned, directly or indirectly, by the Company.

          (3) Conflicting
Agreements. This Agreement and the Note (collectively, at any
time, the “Loan Documents”), do not conflict with, or require the consent of any party to, any
other agreement to which the Company is a party or by which it or its property may be bound or
affected, and do not conflict with any provision of the Company’s bylaws, articles of
incorporation, or other organizational documents.

          (4) Compliance. The Company and, to the extent contemplated hereunder, each
Subsidiary, if any, is in compliance with all of the terms of the Loan Documents.

          (5) Binding Agreement. The Loan Documents create legal, valid, and binding
obligations of the Company which are enforceable in accordance with their terms, except to the
extent that enforcement may be limited by applicable bankruptcy, insolvency, or similar laws
affecting creditors’ rights generally.

     SECTION 15. Affirmative Covenants. Unless otherwise agreed to in writing by FCW, while this
Agreement is in effect, the Company agrees to and with respect to Subsections 15(A) through 15(F)
hereof, agrees to cause each Subsidiary, if any, to:

          (A) Corporate Existence, Licenses. (i) Preserve and keep in full force and effect its
existence and good standing in the jurisdiction of its incorporation or formation; (ii)
qualify and remain qualified to transact business in all jurisdictions where such qualification is
required; and (iii) obtain and maintain all licenses, certificates, permits, authorizations, approvals, and
the like which are material to the conduct of its business or required by law, rule, regulation,
ordinance, code, order, and the like (collectively, “Laws”).

          (B) Compliance with Laws. Comply in all material respects with all applicable Laws,
including, without limitation, all Laws relating to environmental protection.In addition,
the Company agrees to cause all persons occupying or present on any of its properties, and to
cause each Subsidiary, if any, to cause all persons occupying or present on any of its properties,
to comply in all material respects with all environmental protection Laws.

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 6

          (C) Insurance. Maintain insurance with insurance companies or associations
acceptable to FCW in such amounts and covering such risks as are usually carried by companies
engaged in the same or similar business and similarly situated, and make such increases in the
type or amount of coverage as FCW may request. At FCW’s request, all policies (or such other
proof of compliance with this Subsection as may be satisfactory to FCW) shall be delivered to
FCW.

          (D) Property Maintenance. Maintain all of its property that is necessary to or useful
in the proper conduct of its business in good working condition, ordinary wear and tear
excepted.

          (E) Books and Records. Keep adequate records and books of account in which
complete entries will be made in accordance with generally accepted accounting principles
(“GAAP”) consistently applied.

          (F) Inspection. Permit FCW or its agents, upon reasonable notice and during normal
business hours or at such other times as the parties may agree, to examine its properties,
books, and records, and to discuss its affairs, finances, and accounts, with its respective officers,
directors, employees, and independent certified public accountants.

          (G) Reports and Notices. Furnish to FCW:

               (1) Annual Financial Statements. As soon as available, but in no event more
than 90 days after the end of each fiscal year of the Company occurring during the term
hereof, annual consolidated and consolidating financial statements of the Company and its consolidated
Subsidiaries, if any, prepared in accordance with GAAP consistently applied. Such financial
statements shall: (a) be audited by independent certified public accountants selected by the
Company and acceptable to FCW; (b) be accompanied by a report of such accountants
containing an opinion thereon acceptable to FCW; (c) be prepared in reasonable detail and in
comparative form; and (d) include a balance sheet, a statement of income, a statement of
retained earnings, a statement of cash flows, and all notes and schedules relating thereto.

               (2) Interim Financial Statements. As soon as available, but in no event more
than 45 days after the end of each fiscal quarter, a consolidated balance sheet of the Company
and its consolidated Subsidiaries, if any, as of the end of such quarter, a consolidated
statement of income for the Company and its consolidated Subsidiaries, if any, for such period and for
the period year to date, and such other interim statements as FCW may specifically request, all
prepared in reasonable detail and in comparative form in accordance with GAAP consistently
applied and certified by an authorized officer or employee of the Company acceptable to FCW.

               (3) Notice of Default. Promptly after becoming aware thereof, notice of the
occurrence of an Event of Default or a Potential Default.

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 7

               (4) Notice of Non-Environmental Litigation. Promptly after the
commencement thereof, notice of the commencement of all actions, suits, or proceedings before
any court, arbitrator, or governmental department, commission, board, bureau, agency, or
instrumentality affecting the Company or any Subsidiary which, if determined adversely to the
Company or any such Subsidiary, could have a material adverse effect on the financial
condition, properties, profits, or operations of the Company or any such Subsidiary.

               (5) Notice of Environmental Litigation. Promptly after receipt thereof, notice
of the receipt of all pleadings, orders, complaints, indictments, or any other communication
alleging a condition that may require the Company or any Subsidiary to undertake or to
contribute to a cleanup or other response under environmental Laws, or which seek penalties,
damages, injunctive relief, or criminal sanctions related to alleged violations of such Laws,
or which claim personal injury or property damage to any person as a result of environmental
factors or conditions.

               (6) Bylaws and Articles. Promptly after any change in the Company’s bylaws or
articles of incorporation (or like documents), copies of all such changes, certified by the
Company’s Secretary.

               (7) Other Information. Such other information regarding the condition or
operations, financial or otherwise, of the Company or any Subsidiary as FCW may from time to
time reasonably request, including but not limited to copies of all pleadings, notices, and
communications referred to in Subsections 15(G)(4) and (5) above.

               (8) Financial Certificate. Together with each set of financial statements
furnished to FCW pursuant to Section 15(G)(1), and each quarterly statement submitted pursuant
to Section 15(G)(2) for a period corresponding to a period for which one or more of the
financial covenants set forth in Section 17 hereof are required to be tested, a certificate of an
officer or employee of the Company acceptable to FCW setting forth calculations showing compliance
with each of the financial covenants that require compliance at the end of the period for
which the statements are being furnished.

          (H) Certain
Organizational Changes. Provide FCW with prior notice (and as early as
practicable) of any merger, consolidation reorganization under a different provision of law,
acquisition of all or a material part of the assets of another organization, change of name,
adoption of any trade name, or creation of any Subsidiary, affiliate or material joint venture(s).
For purposes of this covenant, joint venture transaction(s), which alone or in the aggregate exceed
$1,000,000, are considered material.

     SECTION 16. Negative Covenants. Unless otherwise agreed to in writing by FCW, which agreement
will not be unreasonably withheld, while this Agreement is in effect, the Company will not:

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 8

          (A) Borrowings. Create, incur, assume, or allow to exist, directly or indirectly, any
indebtedness or liability for borrowed money (including trade or bankers’ acceptances),
letters of credit, or the deferred purchase price of property or services (including capitalized leases),
except for: (i) debt to FCW; (ii) accounts payable to trade creditors incurred in the
ordinary course of business; and (iii) current operating liabilities (other than for borrowed money)
incurred in the ordinary course of business; (iv) debt of the Company to Bank of America in an
amount not to exceed $12,000,000.00 and all extensions, renewals, and refinancings thereof;
(v) (vi) letters of credit issued by any bank for the account of the Company in an aggregate face
amount not to exceed $5,000,000,00 at any one time outstanding; and (vii) capitalized leases
existing on the date hereof existing from time to time.

          (B) Liens. Create, incur, assume, or allow to exist any mortgage, deed of trust, pledge,
lien (including the lien of an attachment, judgment, or execution), security interest, or
other encumbrance of any kind upon any of its property, real or personal (collectively, “Liens”).
The foregoing restrictions shall not apply to: (i) Liens in favor of FCW or CoBank; (ii) Liens
for taxes, assessments, or governmental charges that are not past due; (iii) Liens and deposits
under workers’ compensation, unemployment insurance, and social security Laws; (iv) Liens and
deposits to secure the performance of bids, tenders, contracts (other than contracts for the
payment of money), and like obligations arising in the ordinary course of business as
conducted on the date hereof; (v) Liens imposed by Law in favor of mechanics,
materialmen, warehousemen, and like persons that secure obligations that are not past due; and (vi)
easements, rights-of-way, restrictions, and other similar encumbrances which, in the aggregate, do not
materially interfere with the occupation, use, and enjoyment of the property or assets
encumbered thereby in the normal course of its business or materially impair the value of the
property subject thereto.

          (C) Transfer of Assets. Sell, transfer, lease, or otherwise dispose of any of its assets,
except in the ordinary course of business.

          (D) Contingent Liabilities. Assume, guarantee, become liable as a surety, endorse,
contingently agree to purchase, or otherwise be or become liable, directly or indirectly
(including, but not limited to, by means of a maintenance agreement, an asset or stock
purchase agreement, or any other agreement designed to ensure any creditor against loss), for or on
account of the obligation of any person or entity, except by the endorsement of negotiable
instruments for deposit or collection or similar transactions in the ordinary course of the
Company’s business.

          (E) Change in Business. Engage in any business activities or operations substantially
different from or unrelated to the Company’s present business activities or operations.

     SECTION 17. Financial Covenants. Unless otherwise agreed to in writing, while this
Agreement is in effect:

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 9

          (A) Working Capital. The Company will maintain, on a consolidated basis, current
assets in excess of current liabilities of at least Fifteen Million Dollars ($15,000,000),
measured on a quarterly basis beginning January 31, 2008.

          (B) Tangible
Net Worth.The Company will maintain, on a consolidated basis, a
“Tangible Net Worth” equal to at least Thirty-Two Million Five Hundred Thousand Dollars
($32,500,000.00), measured on a quarterly basis. “Tangible Net Worth” means the value of
total assets (including leaseholds and leasehold improvements and reserves against assets but
excluding goodwill, patents, trademarks, trade names, organization expense, unamortized debt
discount and expense, capitalized or deferred research and development costs, deferred
marketing expenses, and other like intangibles, and monies due from affiliates, officers,
directors, employees, shareholders, members or managers) less total liabilities,
including but not limited to accrued and deferred income taxes, but excluding the non-current portion of
Subordinated Liabilities. “Subordinated Liabilities” means liabilities subordinated to
the Borrower’s obligations to FCW in a manner acceptable to FCW in its sole discretion.

          (C) EBITDA. The Company will maintain an “EBITDA” of at least Seven Million
Five Hundred Thousand Dollars ($7,500,000.00). “EBITDA” means net income, less income or
plus loss from discontinued operations and extraordinary items, plus income taxes,
plus interest expense, plus depreciation, depletion, and amortization. This covenant will be calculated at
the end of each reporting period for which FCW requires financial statements, using the results of
the twelve-month period ending with that reporting period. The current portion of long-term
liabilities will be measured as of the last day of the calculation period.

     SECTION 18. Events of Default. Each of the following shall constitute an “Event of
Default” under this Agreement:

          (A) Payment Default. The Company should fail to make any payment when due.

          (B) Representations and Warranties. Any representation or warranty made or
deemed made by the Company herein or in the Note, application, agreement, certificate, or
other document related to or furnished in connection with this Agreement or the Note, shall prove to
have been false or misleading in any material respect on or as of the date made or deemed
made.

          (C) Certain Affirmative Covenants. The Company or, to the extent required
hereunder, any Subsidiary should fail to perform or comply with Sections 15(A) through
15(G)(2), and 15(G)(6) and such failure continues for 15 days after written notice thereof
shall have been delivered by FCW to the Company.

          (D) Other Covenants and Agreements. The Company or, to the extent required
hereunder, any Subsidiary should fail to perform or comply with any other covenant or
agreement contained herein or in any other Loan Document or shall use the proceeds of any loan
for an unauthorized purpose.

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 10

          
(E) Cross-Default. The Company should, after any applicable grace period, breach or
be in default under the terms of any other agreement between the Company and FCW.

          
(F) Other Indebtedness. The Company or any Subsidiary should fail to pay when due
any indebtedness to any other person or entity for borrowed money or any long-term obligation
for the deferred purchase price of property (including any capitalized lease), or any other
event occurs which, under any agreement or instrument relating to such indebtedness or obligation,
has the effect of accelerating or permitting the acceleration of such indebtedness or obligation,
whether or not such indebtedness or obligation is actually accelerated or the right to
accelerate is conditioned on the giving of notice, the passage of time, or otherwise.

          (G) Judgments. A judgment, decree, or order for the payment of money shall be
rendered against the Company or any Subsidiary and either: (i) enforcement prceedings shall
have been commenced; (ii) a Lien prohibited under Section 10(B) hereof shall have been
obtained; or (iii) such judgment, decree, or order shall continue unsatisfied and in effect
for a period of 20 consecutive days without being vacated, discharged, satisfied, or stayed pending
appeal.

          (H) Insolvency. The Company or any Subsidiary shall: (i) become insolvent or shall
generally not, or shall be unable to, or shall admit in writing its inability to, pay its debts as
they.come due; or (ii) suspend its business operations or a material part thereof or make an
assignment for the benefit of creditors; or (iii) apply for, consent to, or acquiesce in the
appointment of a trustee, receiver, or other custodian for it or any of its property or, in the
absence of such application, consent, or acquiescence, a trustee, receiver, or other custodian
is so appointed; or (iv) commence or have commenced against it any proceeding under any
bankruptcy, reorganization, arrangement, readjustment of debt, dissolution, or liquidation Law
of any jurisdiction.

          (I) Material Adverse Change. Any material adverse change occurs, as reasonably determined
by FCW, in the Company’s financial condition, results of operation, or ability to perform its
obligations hereunder or under any instrument or document contemplated hereby.

     SECTION 19. Remedies. Upon the occurrence and during the continuance of an Event of Default
or any Potential Default, FCW shall have no obligation to continue to extend credit to the
Company and may discontinue doing so at any time without prior notice. For all purposes hereof,
the term “Potential Default” means the occurrence of any event which, with the passage of time
or the giving of notice or both would become an Event of Default, In addition, upon the
occurrence and during the continuance of any Event of Default, FCW may, upon notice to the
Company, terminate any commitment and declare the entire unpaid principal balance of the loans,
all accrued interest thereon, and ail other amounts payable under this Agreement, all
Supplements, and the other Loan Documents to be immediately due and payable. Upon such a
declaration, the unpaid principal balance of the loans and all such other amounts shall become
immediately due and payable, without protest, presentment, demand, or further notice of any

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page11

kind, all of which are hereby expressly waived by the Company. In addition, upon such an
acceleration:

          (A) Enforcement. FCW may proceed to protect, exercise, and enforce such rights and
remedies as may be provided by this Agreement, any other Loan Document or under Law. Each
and every one of such rights and remedies shall be cumulative and may be exercised from time
to time, and no failure on the part of FCW to exercise, and no delay in exercising, any right
or remedy shall operate as a waiver thereof, and no single or partial exercise of any right or
remedy shall preclude any other or future exercise thereof, or the exercise of any other right.
Without limiting the foregoing, FCW may hold and/or set off and apply against the Company’s
obligations to FCW any cash collateral held by FCW, or any balances held by FCW for the
Company’s account (whether or not such balances are then due).

          (B) Application of Funds. CoBank may apply all payments received by it to the
Company’s obligations to FCW in such order and manner as FCW may elect in its sole
discretion.

          In addition to the rights and remedies set forth above: (i) if the Company fails to make any
payment when due, then at FCW’s option in each instance, such payment shall bear interest from the
date due to the date paid at 2% per annum in excess of the rate(s) of interest that would
otherwise be in effect on that loan; and (ii) after the maturity of any loan (whether as a result
of acceleration or otherwise), the unpaid principal balance of such loan (including without
limitation, principal, interest, fees and expenses) shall automatically bear interest at 2% per
annum in excess of the rate(s) of interest that would otherwise be in effect on that loan. All
interest provided for herein shall be payable on demand and shall be calculated on the basis of a
year consisting of 365 days.

     SECTION 20. Broken Funding Surcharge. Notwithstanding any provision contained in the Note
giving the Company the right to repay any loan prior to the date it would otherwise be due and
payable, the Company agrees to provide three Business Days’ prior written notice for any prepayment
of a fixed rate balance and that in the event it repays any fixed rate balance prior to its
scheduled due date or prior to the last day of the fixed rate period applicable thereto (whether
such payment is made voluntarily, as a result of an acceleration, or otherwise), the Company will
pay to CoBank a surcharge in an amount equal to the greater of: (i) an amount which would result in
FCW being made whole (on a present value basis) for the actual or imputed funding losses incurred
by FCW as a result thereof; or (ii) $300.00. Notwithstanding the foregoing, in the event any fixed
rate balance is repaid as a result of the Company refinancing the loan with another lender or by
other means, then in lieu of the foregoing, the Company shall pay to CoBank a surcharge in an
amount sufficient (on a present value basis) to enable FCW to maintain the yield it would have
earned during the fixed rate period on the amount repaid. Such surcharges will be calculated in
accordance with methodology established by FCW (a copy of which will be made available to the
Company upon request).

 

 

			
	AGREEMENT NO. 3789055-101
	 	Page 12

     SECTION 21. Complete Agreement, Amendments. This Agreement, the Note, and all other
instruments and documents contemplated hereby and thereby, are intended by the parties to be a
complete and final expression of their agreement. No amendment, modification, or waiver of any
provision hereof or thereof, and no consent to any departure by the Company herefrom or therefrom,
shall be effective unless approved by FCW and contained in a writing signed by or on behalf of
FCW. and then such waiver or consent shall be effective only in the specific instance and for the
specific purpose for which given. Additionally, any headings used in this Agreement are inserted
only as a matter of convenience and for reference, and in no way define, limit or describe the
scope or intent of any term or provision. As used herein, the word “including” means “including
without limitation” and/or “including but not limited to”.

     SECTION 22. Applicable Law. Except to the extent governed by applicable federal law, this
Agreement and the Note shall be governed by and construed in accordance with the laws of the State
of California, without reference to choice of law doctrine.

     SECTION 23. Notices. All notices hereunder shall be in writing and shall be deemed to be duly
given upon delivery if personally delivered or sent by telegram or facsimile transmission, or 3
days after mailing if sent by express, certified or registered mail, to the parties at the
following addresses (or such other address for a party as shall be specified by like notice):

	 	 	 	 	 
	If to FCW, as follows:

	 	If to the Company, as follows:
	 	 
	 
	 	 	 	 
	Farm Credit West, PCA

	 	Calavo Growers, Inc.	 	 
	2929 W. Main Street, Suite A

	 	Attn: Vice President-Finance	 	 
	Visalia, CA 93291-5700

	 	1141-A Cummings Road

Santa Paula, CA 93060	 	 
	Attention: James Neeley

	 	Fax No: (805) 921-3232	 	 
	Fax No. : 559-627-4728
	 	 	 	 

     SECTION 24. Taxes and Expenses. To the extent allowed by law, the Company agrees to pay all
reasonable out-of-pocket costs and expenses (including the fees and expenses of counsel retained
by FCW) incurred by FCW in connection with the administration, collection, and enforcement of this
Agreement and the other Loan Documents, including, without limitation, all costs and expenses
incurred in perfecting, maintaining, determining the priority of, and releasing any security for
the Company’s obligations to FCW, and any stamp, intangible, transfer, or like tax payable in
connection with this Agreement or any other Loan Document.

     SECTION 25. Effectiveness and Severability. This Agreement shall continue in effect until:
(i) all indebtedness and obligations of the Company under this Agreement, the Note, and all other
Loan Documents shall have been paid or satisfied; and (ii) FCW has no commitment to extend credit
to or for the account of the Company hereunder. Any provision of this Agreement or any other Loan
Document which is prohibited or unenforceable in any jurisdiction shall, as to

 

 

			
	AGREEMENT NO, 3789055-101
	 	Page 13

such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof or thereof.

     SECTION 26. Successors and Assigns. This Agreement, the Note, and the other Loan
Documents shall be binding upon and inure to the benefit of the Company and FCW and their
respective successors and assigns, except that the Company may not assign or transfer its
rights or obligations under this Agreement, the Note or any other Loan Document without the
prior written consent of FCW.

     SECTION 27. Participations. From time to time, FCW may sell to one or more banks,
financial institutions or other lenders a participation in all or a portion of the Commitment
or other extensions of credit made pursuant to this Agreement. However, no such participation
shall relieve FCW of any commitment made to the Company hereunder, or any obligation FCW may
have to pay patronage due the Company from FCW under the provisions of the bylaws of FCW and
its practices and procedures related to patronage distribution. In connection with the
foregoing, FCW may disclose information concerning the Company and its Subsidiaries to any
participant or prospective participant, provided that such participant or prospective
participant agrees to keep such information, confidential. Accordingly, all interests in the
Commitment that is included in a sale of participation interests shall not be entitled to
patronage distributions. A sale of participation interest may include certain voting rights of
the participants regarding the Commitment hereunder (including without limitation the
administration, servicing and enforcement thereof). FCW agrees to give written notification to
the Company of any sale of participation interests.

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized officers as of the date shown above.

	 	 	 	 	 	 	 	 	 
	FARM CREDIT WEST,
PCA	 	CALAVO GROWERS,
INC.. a California	 	 
	 	 	 	 	Corporation	 	 
	By:

	 	/s/ James K Neely
	 	By:
	 	/s/ Arthur J. Bruno	 	 
	 

	 	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	Arthur J. Bruno,	 	 
	Title:

	 	 S Vice President
	 	Title:
	 	Chief Operating Officer, Chief	 	 
	 

	 	 

	 	 	 	Financial Officer & Corporate	 	 
	 

	 	 	 	 	 	Secretary	 	 
	 
	 

	 	 	 	By:
	 	/s/ Scott H. Runge	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Scott H.  Runge,	 	 
	 

	 	 	 	Title
	 	Treasurer	 	 

 

 

PROMISSORY NOTE

     $12,000,000.00

January 31,2007

          FOR VALUE RECEIVED, on the Maturity Date as set forth in that certain Agreement dated January
31, 2007, or in any amendments thereto (the “Agreement”), the undersigned promises to pay to the
order of Farm Credit West, PCA (the “Payee”), or order, at the place and in the manner set forth
in the Agreement, the principal amount of TWELVE MILLION DOLLARS ($12,000,000.00). The undersigned
promises to pay interest on the principal amount hereof remaining unpaid from time to time from
the date hereon until the date of payment in full, payable as provided below under “Repayment
Terms”.

          This note is given for advances to be made by Payee to the undersigned from time to time in
accordance with the terms and conditions of the Agreement, all the terms and conditions of which
are incorporated herein by reference. Advances, accrued interest, and payments shall be posted by
the Payee upon an appropriate accounting record, shall be prima facie evidence as to all such
amounts and shall be binding on the undersigned absent manifest error. The total of such advances
may not exceed the face amount of this note. This note is executed, delivered and accepted not in
payment of but for the purpose of amending, restating and replacing the following described
obligations, and renewing any unpaid balance(s) evidenced thereby: note dated August 17, 2006, in
the principal amount of $12,000,000.00. Furthermore, this note also evidences an additional loan
advance(s) to the extent the note under exceeds the renewed unpaid balance(s) referred to above.

          Repayment Terms: The undersigned shall pay to Payee, Thirty-six (36) monthly interest only
payments, in the amount billed, beginning on February 01, 2007; and One (1) installment of
interest in the amount billed plus principal of any amount necessary to pay the note in full on
February 1, 2010. Payments, other than those required as specified in this Section or in the
Agreement, may be made at any time and in any amount during the term of this note, unless limited
or prohibited herein or unless otherwise required by FCW in writing. This note is due and payable
in full on February 1, 2010 (“Maturity Date”), at which time the undersigned shall pay the unpaid
principal balance and all accrued interest in full. Any amount of principal hereof which is not
paid when due, whether at stated maturity, by acceleration or otherwise, shall bear interest from
the date when due until said principal is paid in full, payable on demand, at a rate per annum
set forth in the Agreement.

          The makers or endorsers hereof hereby waive presentment for payment, demand, protest, and
notice of dishonor and nonpayment of this note, and all defenses on the ground of delay or of any
extension of time for the payment hereof which may be hereafter given by the holder or holders
hereof to them or either of them or to anyone who has assumed the payment of this note, and it is
specifically agreed that the obligations of said makers or endorsers shall not be in anyway
affected or altered to the prejudice of the holder or holders hereof by reason of the assumption
of payment of the same by any other person or entity.

          The undersigned hereby promises to pay all costs and expenses of any rightful holder hereof
incurred in collecting the undersigned’s obligations hereunder or in enforcing or attempting to
enforce any of such holder’s rights hereunder, including reasonable attorneys’ fees and
disbursements, whether or not an action is filed in connection therewith.

 

 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE. WITH, THE LAWS OF THE
STATE OF CALIFORNIA. REPRESENTATIVES OF FCW ARE NOT AUTHORIZED TO MAKE ANY ORAL AGREEMENTS OR
ASSURANCES. DO NOT SIGN THIS NOTE IF YOU BELIEVE THAT THERE ARE ANY AGREEMENTS OR UNDERSTANDING
BETWEEN YOU AND FCW THAT ARE NOT SET FORTH IN WRITING IN THIS NOTE, THE AGREEMENT OR OTHER LOAN
DOCUMENTS EVIDENCING THE COMMITMENT.

	 	 	 	 	 	 	 
	 

	 	CALAVO GROWERS,
INC.
	 
	 

	 	By
	 	/s/ Arthur J. Burno	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Arthur J . Bruno,	 	 
	 

	 	 	 	Chief Operating Officer, Chief Financial	 	 
	 

	 	 	 	Officer & Corporate Secretary	 	 
	 
	 	 	 	 	 	 
	 

	 	By
	 	/s/ Scott H. Runge	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Scott H . Runge, Treaure	 	 

INDORSEMENT
– The within Note is hereby indorsed by the payee named in the body of said Note
as if the name of the payee were actually executed under the indorsement.

PAY TO THE ORDER OF U.S. AgBANK, FCB, Wichita, Kansas

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]